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T-cells play a critical role in tumor immunity. Indeed, the presence of tumor-infiltrating 
lymphocytes is a predictor of favorable patient prognosis for many indications and is 
a requirement for responsiveness to immune checkpoint blockade therapy targeting 
programmed cell death 1. For tumors lacking immune infiltrate, or for which antigen pro-
cessing and/or presentation has been downregulated, a promising immunotherapeutic 
approach is chimeric antigen receptor (CAR) T-cell therapy. CARs are hybrid receptors 
that link the tumor antigen specificity and affinity of an antibody-derived single-chain 
variable fragment with signaling endodomains associated with T-cell activation. CAR 
therapy targeting CD19 has yielded extraordinary clinical responses against some 
hematological tumors. Solid tumors, however, remain an important challenge to CAR 
T-cells due to issues of homing, tumor vasculature and stromal barriers, and a range 
of obstacles in the tumor bed. Protumoral immune infiltrate including T regulatory cells 
and myeloid-derived suppressor cells have been well characterized for their ability to 
upregulate inhibitory receptors and molecules that hinder effector T-cells. A critical role 
for metabolic barriers in the tumor microenvironment (TME) is emerging. High glucose 
consumption and competition for key amino acids by tumor cells can leave T-cells with 
insufficient energy and biosynthetic precursors to support activities such as cytokine 
secretion and lead to a phenotypic state of anergy or exhaustion. CAR T-cell expansion 
protocols that promote a less differentiated phenotype, combined with optimal receptor 
design and coengineering strategies, along with immunomodulatory therapies that also 
promote endogenous immunity, offer great promise in surmounting immunometabolic 
barriers in the TME and curing solid tumors.
Keywords: immunotherapy, chimeric antigen receptor, T-cells, gene-engineering, immunometabolism, solid 
tumors, tumor microenvironment
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NATURAL TUMOR iMMUNiTY AND 
ReSPONSe TO iMMUNOTHeRAPY
immune Checkpoint Blockade
T  lymphocytes play a critical role in tumor immunity through 
the recognition of tumor-associated antigens processed and 
presented as peptides at the cell surface by major histocompat-
ibility complex (MHC) molecules (1). For various tumor types, 
the presence of tumor-infiltrating T lymphocytes (TILs) predicts 
longer disease-free survival and overall patient survival (2–6). 
Cancers employ numerous mechanisms of immune evasion 
(7) that dampen T-cell activity, which in some patients can be 
successfully reversed by monoclonal antibodies (mAbs) targeting 
immune checkpoints, such as cytotoxic T lymphocyte-associated 
protein 4 (CTLA-4), and the programmed cell death 1 (PD-1)/
PD ligand 1 (PD-L1) axis. These immunomodulatory mAbs have 
enabled regression of a range of malignancies including mela-
noma (8, 9), lung (10), bladder (11), Hodgkin’s lymphoma (12), 
renal-cell carcinoma (13), ovarian (14), as well as gastrointestinal 
and endometrial cancers with DNA mismatch-repair defects (15), 
thus providing proof that the majority of solid tumor types can be 
spontaneously recognized by the host’s T-cells. PD-1 inhibition 
alone is active in about 30% of cancer patients, but in combination 
with CTLA-4 the fraction of responding metastatic melanoma 
patients increases to 57% (16). Notably, clinical responses to 
immunotherapy are usually associated with durability (17).
A number of studies have attempted to elucidate mechanisms 
underlying resistance to checkpoint blockade. The presence of 
CD8+ T-cells within the tumor or its invasive margin is a key 
requirement for responses to PD-1 inhibition (18). Many studies 
indicate that the neoantigen load may also be an influencing factor 
(19–22). However, as the case of Merkel-cell carcinoma (MCC) 
has shown, the quality of tumor epitopes and the corresponding 
TILs, and not only the mutation rate, can confer sensitivity to 
checkpoint blockade; MCC that is virally induced and having a 
low mutation rate responds similar to checkpoint blockade as 
MCC caused by ultraviolet radiation (23, 24). The presence of 
CD8+ TILs has been linked to the expression of a type I interferon 
(IFN) signature in tumors (25, 26) and the recruitment of a subset 
of CD103+/CD8α+ DCs driven by the transcription factor Batf3 
(27, 28). WNT/β-catenin signaling upregulation may be one of 
the tumor cell-intrinsic pathways driving a non-T-cell inflamed 
phenotype, at least in metastatic melanoma (29) for which a 
genetically engineered mouse model revealed reduced expres-
sion of the chemokine CCL4, impaired recruitment of Batf3+ 
DCs and T-cells, and resistance to checkpoint blockade (29). 
Interestingly, commensal bacteria in the gut can also shape innate 
immunity and responses to immune checkpoint therapy (30–32). 
Finally, metabolic circuitries play an important role in regulating 
immune function in tumors. It has recently been demonstrated 
that CTLA-4, PD-1, and PD-L1 blockade can restore glucose 
levels in the tumor microenvironment (TME), thereby improving 
T-cell fitness. Anti-PD-L1 mAb was specifically shown to block 
the mechanistic target of rapamycin [mTOR, a central regulator 
of metabolism and physiology (33)] and decrease the expression 
of glycolytic enzymes in tumor cells (34). Further, for PD-L1+ 
renal-cell carcinoma patients, non-responsiveness to PD-1 block-
ade has been associated with metabolic gene upregulation as well 
as of solute transport functions such as UGT1A family members, 
whereas responders present an immune response profile includ-
ing upregulation of CCL3, a chemokine involved in leukocyte 
migration (35).
TiL and Chimeric Antigen Receptor (CAR) 
T-Cell Therapy
Another powerful form of immunotherapy is adoptive T-cell 
therapy (ACT), which entails the ex vivo expansion of tumor-
specific T-cells and their infusion into a patient. For TIL 
therapy, in which T  lymphocytes are enriched from tumor 
biopsies, patients are typically lymphodepleted and receive 
high-dose interleukin-2 (IL-2) (36–38). TIL therapy has proven 
successful in advanced metastatic melanoma, mediating objec-
tive responses in about 50% of patients, and durable complete 
responses in up to 20% of patients receiving a single TIL infusion 
(36). It is now evident that in the case of metastatic melanoma 
an important target of TILs are mutated gene products (39). 
TIL therapy has also been anecdotally successful in common 
carcinomas (40), suggesting that this approach could be applied 
to other solid tumor indications. For various reasons, however, 
ranging from tumor vasculature barriers to a lack of type I IFN 
signaling, not all tumors are infiltrated by T-cells at baseline 
(27, 41–43).
In the absence of endogenous T-cell infiltrate due to aber-
rant antigen processing and presentation, for example, which 
precludes the use of TIL therapy and immune checkpoint 
blockade, a promising solution for treating cold tumors is 
the transfer of mAb-modified T-cells, so-called CAR T-cells 
(39). In recent years, CD19-targeted CAR T-cell therapy has 
yielded spectacular clinical responses against hematologic 
liquid tumors (44), including up to 90% complete response 
in relapsed or treatment-refractory acute lymphoblastic leu-
kemia (ALL) patients (45). In the solid TME, however, T-cells 
face a battery of physical and immunometabolic barriers 
(46, 47), to which CAR T-cells, like endogenous T-cells, are 
vulnerable (48, 49). CAR T-cells may thus similarly require 
combinatorial regimens of immunomodulation such as 
kinase inhibitors (50), chemotherapy (51), radiotherapy (RT) 
(52), or checkpoint blockade (53), to unleash their full thera-
peutic potential (54–56). CAR T-cells can also be armored 
through additional gene modification (57). For example, 
they have been coengineered to express stimulatory ligands, 
such as CD40 ligand (CD40L) (58), or to secrete stimula-
tory cytokines, such as IL-12 (57), for improved antitumor 
responses. With an emerging awareness of the role played by 
metabolism in both cancer progression and T-cell activity 
in the TME (59), it is apparent that further development of 
CAR T-cell therapy for maximizing functionality in harsh, 
nutrient-depleted conditions is critical. Here, we review 
the design and function of CAR T-cells, immunometabolic 
barriers in the solid TME, and different ex vivo expansion, 
coengineering and combinatorial therapy approaches for 
overcoming them.
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CAR T-CeLL eNGiNeeRiNG
Basic CAR Design
Chimeric antigen receptors, first conceived in the late 1980s 
(60), are hybrid receptors comprising (i) an extracellular tumor-
binding moiety, typically an Ab-derived single-chain variable 
fragment (scFv), (ii) a hinge/spacer, (iii) a transmembrane (TM) 
region, and (iv) various combinations of intracellular signaling 
domains associated with T-cell activation (61). First-generation 
CARs include the endodomain of CD3ζ only (for signal 1 of 
T-cell activation), while second- and third-generation CARs 
also have one or more costimulatory endodomains (for signal 
2), respectively (Figure  1) (62). Finally, armored CAR T-cells 
are further gene modified to express or block molecules and/
or receptors to enhance immune activity. Patient responses to 
first-generation CAR T-cells were disappointing, probably due to 
poor expansion and persistence (63–65) as a result of an anergic 
phenotype (66–68), and most ongoing trials involve second-
generation CARs incorporating either CD28 or 4-1BB (CD137) 
(39, 69). CARs can be transiently expressed in primary T-cells 
by RNA electroporation, typically for about 1 week with current 
technology, or they can be stably incorporated into the genome 
by lentiviral or gamma-retroviral transduction (70), as well as by 
transposon/transposase-mediated integration using the sleeping 
beauty system (71). RNA electroporation along with dosing 
escalation is often used in the testing of new CARs in the clinic. 
To minimize toxicity, molecules secreted by armored CAR T-cells 
can be placed under an inducible promoter (72). To date, there 
have been no safety issues related to viral or transposon-mediated 
genomic integration of CARs (38, 73).
Unlike T-cell receptors (TCRs) that are MHC restricted, CARs 
can potentially bind any cell surface-expressed antigen and can 
thus be more universally used to treat patients. CARs have been 
developed against not only proteins, including the pMHC com-
plex (74), but also against carbohydrates and glycolipids, as well 
as targets upregulated in the tumor stroma (75) and the tumor 
vasculature (42). Notably, not all scFvs are suitable for CAR 
development. A recent study demonstrated antigen-independent 
clustering of an anti-GD2 CAR, caused by the framework region 
sequences, thereby exhausting the cells and limiting antitumor 
responses. Interestingly, it was further shown that 4-1BB was 
superior to CD28 in alleviating exhaustion from this tonic 
signaling (76). In addition, caution should be taken in the use of 
scFvs of murine origin, as human-anti-mouse Ab responses can 
deplete the transferred CAR T-cells, and even result in patient 
death by anaphylactic shock following multiple infusions (77, 
78). Interestingly, similar to TCRs, increasing receptor-binding 
strength can augment T-cell function, but there is an affinity 
threshold beyond which there is no further gain in activity, and 
target density impacts CAR T-cell activation (79–81). Along with 
scFv, other tumor-binding moieties including an anti-integrin 
peptide α5β6 (82), heregulin (83), interleukin 13-zetakine (84), 
NKG2D (85), vasculature endothelial growth factor (VEGF) 
(86), and TCRs (87) have been incorporated into functional 
CARs. Finally, universal CARs, including an avidin ectodomain 
(88) and an anti-FITC scFv (89) for recognizing targets bound 
by biotinylated and FITC-labeled mAbs, respectively, have been 
developed.
CAR T-Cell Safety and Next-Generation 
Receptor Design
Chimeric antigen receptor T-cells are a potent living drug and a 
primary consideration in their development is the choice of target 
antigen. Ideally, it is highly expressed on the tumor and not at 
all on normal cells. Currently, there are about 30 solid tumor 
antigens being evaluated for CAR therapy including mesothelin, 
carcinoembryonic antigen (CEA), the diganglioside GD2, inter-
leukin 13 receptor alpha (IL13Ra), human epidermal growth 
factor 2 (HER-2), fibroblast-activating protein (FAP), and L1 cell 
adhesion molecule (L1CAM) (90, 91). Unfortunately, there have 
been instances of severe on-target/off-site toxicity (92) such as 
a HER-2 CAR that may have caused patient death via reactivity 
with low levels of cognate antigen expressed on lung epithelium 
(93). One approach to circumvent this is to use a lower affinity 
scFv such that the CAR T-cells are only activated in the pres-
ence of high cell-surface expression of antigen (i.e., on the tumor 
cells only) (94–96). Or one can target an antigen that is tumor 
restricted, such as epidermal growth factor receptor variant III 
(EGFRvIII) (97), but there are few such examples.
In recent years various novel, next-generation engineering 
strategies have been devised to improve CAR T-cell safety. For 
example, the signaling can be split by coexpressing two CARs, 
one incorporating CD3ζ and the other the costimulatory 
endodomain, such that the T-cell will only be fully activated 
when both receptors are engaged (98, 99). Bispecific tandem 
CARs (TanCARs; the extracellular domain of one receptor can 
engage two distinct antigens) (100) have also been developed that 
synergistically enhance T-cell activity levels when coengaged. 
More recently, novel synthetic Notch-based receptors have 
been designed that enable combinatorial activation of T-cells— 
binding by the Notch-based CAR upregulates expression of the 
second CAR (101, 102). In addition, innovative ON-Switch/
Remote Control CARs have been developed that restrict T-cell 
activation to tumor cell antigen encounter in the presence of a 
remotely provided heterodimerizing small molecule that links 
the antigen-binding receptor with intracellular components that 
initiate signaling (103). Finally, it is also possible to gene-modify 
CAR T-cells with various suicide genes or safety switches such as 
inducible caspase 9 to cause rapid T-cell destruction in the case 
of an adverse reaction in a treated patient (104, 105). In the event 
of CAR T-cell toxicity, such as cytokine release syndrome (CRS), 
early and aggressive supportive patient care is critical. The current 
mainstay treatment for CRS is IL-6 receptor blockade with the 
monoclonal Ab tocilizumab, but in the case of neurologic toxici-
ties corticosteroids are employed (106).
CAR T-Cell Activity As a Function of 
Receptor Design
The distance between a T-cell and its target antigen-presenting 
cell (APC) of approximately 15 nm is dictated by the TCR–pMHC 
interaction and is critical for the exclusion of large phosphatases 
FiGURe 1 | Properties of first-, second-, and third-generation chimeric antigen receptor (CAR) T-cells. CARs comprise an extracellular tumor-binding 
moiety, typically a single-chain variable fragment (scFv), followed by a hinge/spacer of varying length and flexibility, a transmembrane (TM) region, and various 
combinations of endodomains associated with T-cell signaling. While first-generation CARs include the endodomain of CD3ζ, second- and third-generation CARs 
also have one or more costimulatory endodomain, respectively. The most commonly used costimulatory endodomains are from CD28 and 4-1BB. CAR T-cell 
functionality can vary based on design (scFv affinity, hinge/spacer length, TM domain, etc.) and generation. In general, the 4-1BB endodomain confers the highest 
level of in vivo persistence and resistance to exhaustion. Metabolically, second-generation CD28-based CAR T-cells exhibit enhanced aerobic glycolysis as 
compared to 4-1BB-based ones which demonstrate enhanced respiratory capacity, fatty acid oxidation, and mitochondrial biogenesis. Stimulated CD28-based 
CAR T-cells acquire an effector memory-like phenotype, whereas 4-1BB-based ones take on a central memory-like phenotype.
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such as CD45 and CD148 to the periphery of the immune synapse 
(107), thereby enabling TCR clustering and triggering (1). The 
precise mechanism by which CARs activate T-cells has not been 
fully elucidated, but the hinge/spacer, which governs the spatial 
distance between a CAR T-cell and its target, can significantly 
impact function (108, 109). Various hinge/spacers have been 
incorporated into CARs including regions from CD8α and CD4, 
as well as CH2–CH3 from the Fc domains of IgG1 and IgG4. In 
the case of CH2 spacers derived from IgG4, sequence modifica-
tion is required to prevent Fc receptor binding by myeloid cells 
that can cause activation-induced T-cell death (AICD) (110, 111). 
Most CARs comprise a TM domain from a type I membrane 
protein such as CD4, CD8, CD3ζ, or CD28. Interestingly, it was 
demonstrated that CARs comprising a CD3ζ TM domain engage 
endogenous TCR–CD3 complexes for optimal activity (112). 
CARs can function, however, in the absence of endogenous TCR 
(113), and important efforts are being undertaken to develop 
universal allogeneic T-cell donors for immunotherapy (114).
In general, distal membrane epitopes require a shorter 
hinge/spacer, whereas an epitope that is closer to the tumor cell 
membrane may necessitate a longer and more flexible one to 
facilitate scFv binding and optimal T-cell activity (115). Recently, 
a Strep-tag II has been used to modify spacer length and at the 
same time provide a means of identifying and rapidly purifying 
CAR-engineered T-cells, during both the manufacturing process 
and patient monitoring (116). A notable study comparing three 
L1CAM CARs varying only in hinge/spacer length (short, 
medium, and long) revealed that the CAR conferring the highest 
5Irving et al. Immunometabolic Barriers to T-Cell Therapy
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in  vitro function (long; IgG4 hinge–CH2–CH3 spacer) fared 
poorly in vivo, and, conversely, the weakest CAR in vitro (short; 
IgG4 hinge) performed the best in tumor-bearing mice. The 
authors hypothesized that the limited duration of CAR signaling 
required for in vitro assays does not reflect the recursive rounds 
of activation needed to eradicate a tumor in vivo. Thus, they set 
up a coculture stress test for which CAR T-cells were repeatedly 
harvested and transferred to culture dishes seeded with fresh 
tumor cells. Interestingly, after three rounds, the CAR T-cells 
bearing the long linker (i.e., conferring the best activity in round 
1) underwent the highest level of AICD as a result of upregulated 
FasL–Fas interactions (110). This work highlights a disaccord 
between T-cell responses observed in standard in  vitro testing 
versus in vivo challenges. Establishing in vitro T-cell parameters 
such as receptor affinity/kinetics and two-dimensional interac-
tions (117), functionality upon stress testing (110), gene expres-
sion profiles upon activation, etc., that correlate to maximum 
antitumor responses in vivo is an important area of research for 
the efficient screening of new leads for preclinical and clinical 
testing.
Optimal T-Cell Subsets for CAR Activity
Another important factor governing CAR T-cell activity in vivo 
is the subset of input T-cells used. Based on their differentiation 
and level of maturity, T-cells are presently classified into naïve 
(TN), and four main activated subtypes: stem cell memory (TSCM), 
central memory (TCM), effector memory (TEM), and terminally 
differentiated effector cells (TEFF) (118). For both mouse and 
humans, it has been demonstrated that the less differentiated 
subsets (TSCM and TCM) display better expansion, persistence, 
and antitumor activity in  vivo (119–122). The phenotypic and 
functional properties of human CD8+ TN versus the different 
memory subsets are illustrated in Figure 2. Retrospective studies 
from ACT trials have correlated objective clinical responses in 
patients with the transfer of less differentiated T-cells (123, 124). 
A recent analysis of CD19 CAR-treated patients revealed a cor-
relation between in vivo expansion and the level of infused TSCM 
phenotype (125). There are also studies demonstrating better 
antitumor responses when both CD4+ and CD8+ CAR T-cells are 
transferred (126), and it has proven beneficial to gene-engineer 
virus-specific memory T-cells that can persist long term, pre-
sumably via TCR-mediated survival signals and the quality of 
the original TCR-mediated priming of the cell (127). Although 
T-cell metabolism has long been an active field of study due 
to the remarkable cellular rewiring required to accommodate 
changes in energetic requirements when naïve, quiescent T-cells 
encounter and respond to cognate pMHC, it is only recently that 
it has come to the forefront of cancer research.
iNTeRPLAY BeTweeN THe MeTABOLiC 
ACTiviTY OF T-CeLLS AND FUNCTiON
Metabolic Activity of Naïve T-Cells
All T-cells use glucose as their primary source of fuel for the gen-
eration of adenosine triphosphate (ATP), but there are important 
differences in the metabolic requirements and pathways used by 
naïve, activated, and memory T-cells, which correspond to their 
specific functional state (128). TN cells are quiescent and have lim-
ited biosynthetic needs because their major role is to circulate the 
host with the aim of being primed by an APC. Quiescent T-cells, 
comprising both naïve and memory T-cells, rely on catabolic 
metabolism, whereby nutrients including glucose, fatty acids, and 
amino acids are broken down for fuel (128). Indeed, quiescent 
T-cells mainly undertake oxidative phosphorylation (OXPHOS), 
a process that takes place in the mitochondria involving the 
oxidation of substrates in the tricarboxylic acid (TCA) cycle to 
generate ATP (129) (summarized in Figure 3A). The TCA cycle 
itself is a series of chemical reactions that use metabolic substrates 
to produce reducing agents such as the coenzyme reduced nico-
tinamide adenine dinucleotide (NADH), which donate electrons 
to the electron transport chain. Up to 36 molecules of ATP can be 
generated by OXPHOS per glucose molecule.
Metabolic Activity of effector T-Cells
Upon productive TCR–pMHC engagement and costimulation, 
naïve T-cells become activated and undergo extensive metabolic 
rewiring causing them to enlarge in size, and enabling extensive 
proliferation and the acquisition of effector functions such as 
cytokine secretion (130). Activated T-cells switch to anabolic 
metabolism meaning that nutrients are used to construct molecu-
lar building blocks. This transition is associated with mTOR 
induction, and the expression of the transcription factors Myc 
and hypoxia-inducible factor-1α (HIF-1α) (131, 132). Although 
activated T-cells increase mitochondrial OXPHOS and reactive 
oxygen species production, they also upregulate and rely heavily 
upon aerobic glycolysis (133) to meet their metabolic needs (134, 
135) (Figure 3B). Upon T-cell activation, there is an increase in 
the expression of the glucose receptor Glut1, as well as glycolytic 
enzymes to enable increased import of glucose that is converted 
to glucose-6-phosphate and eventually pyruvate that is finally 
secreted in the form of lactate. It has recently been demonstrated 
that T-cells activated under hypoxic conditions upregulate sig-
nificantly higher levels of Glut1 than under atmospheric oxygen 
(136), but the reactivation of CD8+ T-cells under hypoxia has 
also been shown to switch them toward a poorly proliferative and 
IL-10 secreting phenotype (137). This phenomenon of aerobically 
fermenting glucose to lactate, despite sufficient oxygen to support 
OXPHOS, a process also utilized by tumor cells, which them-
selves are heavy consumers of glucose, is known as the Warburg 
effect (138, 139).
Aerobic glycolysis is energetically less efficient than OXPHOS, 
generating only two molecules of ATP per glucose molecule, but 
the process is rapid and in addition supplies a critical source 
of metabolic intermediates needed for the synthesis of nucleic 
acids, proteins, carbohydrates, and lipids, and it provides a 
means of maintaining the NAD+-NADH redox balance (138). 
Glycolytic metabolites also help to sustain effector functions 
through transcriptional and translation regulation (59). For 
example, glyceraldehyde-3-phosphate promotes IFNγ produc-
tion by relieving its restraint by glyceraldehyde-3-phosphate 
dehydrogenase (140). In addition, Ho et  al. demonstrated that 
phosphophenolpyruvate (141) accumulation can help sustain the 
Ca2+-NFAT pathway, which controls the production of effector 
FiGURe 2 | Differentiation of naïve T-cells to memory subsets upon priming in secondary lymphoid organs. The differentiation state of T-cells depends 
upon the strength and duration of priming naïve T-cells receive from antigen-presenting cells in the secondary lymphoid organs. In general, the more differentiated 
the T-cell, as a result of more robust priming, the lower its proliferative and self-renewal capacity, and the poorer its antitumor control in the context of adoptive T-cell 
therapy. The different memory T-cell subsets can be distinguished based on their expression of various cell-surface markers including the tyrosine phosphatase 
CD45 (full length = CD45RA, truncated form = CD45RO), the lymph node homing receptors, chemokine receptor 7, and CD62 ligand, as well as CD95 (Fas 
receptor), interleukin-2 receptor β-chain, and the costimulatory receptor CD28.
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molecules, by inhibiting ER Ca2+ reuptake. It has been shown that 
activated T-cells can switch between OXPHOS and aerobic glyco-
lysis depending on their environment, but glycolysis is required 
for full effector function—if activated T-cells revert to OXPHOS 
it will be at the expense of IL-2 and IFNγ production (140). In 
addition to glucose, activated T-cells rely upon an extracellular 
supply of glutamine to replenish intermediates for the TCA 
cycle through the process of glutaminolysis, and this can also 
contribute to the citrate pool used for lipid synthesis by reductive 
carboxylation (142, 143). Finally, activated T-cells decrease fatty 
acid oxidation (FAO), decrease pyruvate flux into the TCA cycle, 
and increase glucose flux into the pentose phosphate pathway to 
produce nucleotides for DNA synthesis (Figure 3B).
Metabolic Activity of Memory T-Cells
By contrast, memory T-cells transition from aerobic glycolysis to 
OXPHOS, fueled in part by the catabolism of intracellular fatty 
acids in the mitochondria (144–146). Furthermore, memory 
T-cells have increased mitochondrial mass and activity (147, 148) 
and upregulate mitochondrial biogenesis to build substantial spare 
respiratory capacity (SRC), thereby enabling both survival and 
rapid recall to antigen challenge (130) (Figure 3C). Interestingly, 
memory T-cells activated in vitro increase aerobic glycolysis, and 
consequently IFNγ production, more rapidly than their naive 
counterparts. How this relates to their capacity to compete for 
glucose in the TME remains to be established (149). Moreover, 
memory T-cells can potentially better adapt to a nutrient crisis 
because they have healthier mitochondria (147). AMP-activated 
protein kinase (AMPK) is another important metabolic regulator 
in T-cells that senses a high AMP to ATP ratio and can promote 
catabolic pathways and conservation of energy during metabolic 
stress. AMPK is important for memory T-cell development (150); 
treating activated CD8+ T-cells with either rapamycin (inhibits 
mTOR) or metformin (activates AMPK) to augment catabolic 
pathways enhances CD8+ memory formation (151, 152).
immunometabolism and T-Cell Therapy
It has been observed that several genes involved in metabolism 
are downregulated in exhausted T-cells (153). Moreover, blocking 
leucine or glucose metabolism during T-cell activation leads to an 
anergic phenotype (154). Mechanistically, leucine can stimulate 
mTOR via leucyl-tRNA synthetase and hence low leucine levels 
FiGURe 3 | General metabolic profiles of naïve, activated, and memory T-cells. (A) Naïve T-cells are quiescent and perform catabolic metabolism to 
accommodate basic energy requirements. (B) Activated effector T-cells, whereas switch to anabolic metabolism to meet increasing energy demands as well as for 
biosynthesis to support functionality including proliferation, growth, and cytokine secretion. (C) Memory cells, like naïve cells, are quiescent and perform metabolic 
catabolism. While naïve and memory T-cells mostly rely on oxidative phosphorylation (shown in orange), activated ones are metabolically rewired to upregulate 
aerobic glycolysis (shown in red). Activated T-cells also require glutaminolysis (in green) and the pentose phosphate pathway (in navy blue) to support their activities. 
Memory T-cells rely on fatty acid oxidation (in purple) and they have increased mitochondrial mass and maintain substantial spare respiratory capacity to enable 
survival and rapid recall to antigen challenge. A brief summary of the major metabolic mechanisms is described in the inlet.
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may impair mTOR activation (155, 156). It has also been dem-
onstrated that both PD-1 and CTLA-4 ligation inhibits glycolysis 
in activated T-cells but through distinct mechanisms; CTLA-4 
inhibits Akt via the serine–threonine phosphatase PP2A, while 
PD-1 inhibits Akt phosphorylation by blocking CD28-mediated 
activation of PI3K (157). PD-1 signaling also blocks amino acid 
metabolism but promotes fatty acid β-oxidation (158). With an 
increased appreciation for the high competition for nutrients 
8Irving et al. Immunometabolic Barriers to T-Cell Therapy
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including glucose in the TME which can promote tumor progres-
sion, as well as the dynamic interplay between T-cell phenotype, 
metabolism, and immune checkpoint, it is clear that an important 
consideration in the development of CAR T-cells is how their 
culture prior to transfer, as well as their design, affects their 
metabolic profile.
Traditionally, T-cells for ACT are cultured with high doses of 
IL-2, followed by a rapid expansion protocol comprising agonistic 
anti-CD3 Ab and allogeneic feeder cells (159). However, it is now 
known that TCR signaling coupled with high-dose IL-2 drives 
TEFF differentiation (160) which is not an ideal phenotype for ACT. 
Alternative common gamma chain (γc) signaling cytokines have 
also been assessed for T-cell culture. Naïve mouse T-cells cultured 
in the presence of IL-15 (145) or IL-21 (161), for example, acquire 
phenotypic, functional, and metabolic properties of naturally 
occurring TCM cells. Moreover, IL-15 cultured murine T-cells 
confer superior in vivo antitumor activity than ones cultured in 
IL-2 (162). Similarly, human T-cells cultured with artificial APCs 
and IL-15 exhibit a TCM phenotype, demonstrate clonotypic 
persistence, and can mediate objective clinical responses upon 
transfer (163, 164). Human T-cells cultured in IL-21 also main-
tain a minimally differentiated profile (161, 165). Interestingly, it 
has been demonstrated that IL-15 regulates SRC and oxidative 
metabolism by mitochondrial biogenesis as well as the expression 
of carnitine palmitoyl transferase, a metabolic enzyme involved 
in the rate-limiting step in FAO (145). IL-7 also enhances T-cell 
survival in a metabolically driven manner by Glut1 trafficking via 
STAT5 and Akt (166), as well as by inducing glycerol transport 
(via AQP9) and triglyceride synthesis (167). Finally, metaboli-
cally robust T-cells isolated with the lipophilic cationic dye tetra-
methylrhodamine methyl ester (TMRM; staining can be used 
to distinguish mitochondrial membrane potential) conferred 
enhanced persistence and tumor eradication upon ACT (168).
A T-cell’s commitment between a memory versus effector 
phenotype is governed by its metabolic state (145, 152, 169), 
which in turn is controlled by stimuli from TCR, costimulatory 
and cytokine receptors that converge at common development, 
and differentiation signal transduction pathways including PI3K/
Akt/mTOR and Wnt/β-catenin (130). Thus, small molecule 
modulators of these pathways have been assessed for the in vitro 
culture of T-cells for ACT. Promotion of the canonical Wnt/β-
catenin pathway with the GSK3β inhibitor TWS119, for example, 
favors the formation of TCM and TSCM cells with improved in vivo 
antitumor responses as compared to untreated cells (170). 
Similarly, Akt inhibition during ex vivo priming and expansion 
of T-cells favors TSCM-like cells having higher rates of OXPHOS 
and FAO and enabling enhanced in  vivo tumor control (171). 
Another consideration in T-cell culture for ACT is glucose con-
centration in the media. Although media often comprise about 
5.5 mM glucose (similar to that of blood), many used for ACT 
are in the range of 10–25 mM—this may program high depend-
ency on glucose and thereby further impair T-cell responses 
in the nutrient-deprived TME (169, 172). Interestingly, it has 
been shown that the activation of CD8+ T-cells in the presence 
of 2-deoxyglucose, an inhibitor of glycolysis, enhances memory 
generation and antitumor responses (169). Several amino acids 
have been implicated in immunomodulation including cysteine, 
glutamine, phenylalanine, tryptophan, and arginine (173). It has 
been observed that low arginine, for example, induces the loss 
of CD3ζ and inhibits proliferation and cytokine production by 
T-cells, but that this state can be reversed by exposure to excess 
arginine (174). Recently, it has been further demonstrated that 
the culture of murine T-cells with elevated l-arginine promotes 
the generation of TCM-like cells, shifts the metabolic profile from 
glycolysis to OXPHOS, and endows the T-cells with enhanced 
antitumor activity in vivo (175).
CAR endodomains and Metabolism
As previously mentioned, in recent years, there have been 
important clinical responses to CD19 CAR T-cell therapy against 
hematological tumors including ALL, chronic lymphocytic leu-
kemia (CLL), and diffuse large B cell lymphoma, using second-
generation receptors comprising either CD28 or 4-1BB [reviewed 
in Ref. (44)]. It is oftentimes difficult to compare the success of 
trials because of differences in the study design, including the scFv 
used, the gene transfer protocols, and interventions undertaken 
post-transfer. Initial clinical response rates against ALL have 
been the same for CD19 CAR trials incorporating either CD28 
or 4-1BB (45, 176, 177). In the case of CLL, however, 4-1BB-based 
CAR T-cells appear superior (178), demonstrating persistence of 
greater than 4 years in some patients versus 30 days in the case of 
CD28 (179). Signaling pathways induced by CD28 versus 4-1BB, 
a member of the tumor-necrosis receptor family, are distinct. 
While CD28 activates the PI3K/Akt pathway that can enhance 
glycolysis (180), 4-1BB has been linked to long-term survival of 
T-cells (181). Recently, the metabolic pathways induced by the 
CD28 versus the 4-1BB costimulatory endodomain of second-
generation CD19 CAR T-cells were described for the first time 
(182). T-cells engineered with a 4-1BB-bearing CAR had an 
increased frequency of TCM phenotype, mitochondrial biogen-
esis, and oxidative metabolism upon activation, and had greater 
survival, as compared to the CD28-based CAR T-cells that had 
enhanced aerobic glycolysis and a predominantly TEM phenotype 
(Figure 1). This work has important implications in the choice 
of CAR costimulatory endodomains for targeting different solid 
TMEs. For example, in the case of a tumor such as BRAF V600E 
melanoma, which has a high glycolytic rate (183), it may be pru-
dent to develop a CAR incorporating 4-1BB. Pretreatment with a 
BRAF inhibitor may also help in restoring glucose levels prior to 
ACT for improved T-cell activity in the TME. Alternatively, it may 
be beneficial to transfer both CD28 and 4-1BB-based CAR T-cells 
for both immediate effector and persistent antitumor activity.
ARMOReD CAR T-CeLLS AND 
COMBiNATiON THeRAPieS TO 
OveRCOMe iMMUNOMeTABOLiC 
OBSTACLeS iN SOLiD TUMORS
immunometabolic Obstacles in Solid 
Tumors
The clinical efficacy of CAR T-cells against solid tumors remains 
to be proven (184). The two most successful trials to date involve 
HER-2 CAR T-cells against sarcoma, for which 4/17 patients 
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showed stable disease (185), and GD2 CAR T-cells to treat 
neuroblastoma, for which 3/11 patients underwent a complete 
response (186). There are various physical and physiological hur-
dles faced by T-cells in the context of solid tumors (46). To begin 
with, T-cells must successfully, (i) home to the tumor bed, often 
in the face of mismatches between T-cell chemokine receptors 
and chemokines present in the TME. Furthermore, T-cells must 
migrate along, (ii) an aberrant vasculature that is not conducive 
to transendothelial migration of T-cells due to downregulation 
of adhesion molecules (ICAM-1) (42) and the upregulation of 
FasL (187), etc., and they can encounter, (iii) additional barriers 
in the stroma, including a dense collagen matrix and suppres-
sive cancer-associated fibroblasts (47). If T-cells are successful 
in penetrating the tumor bed, there they can face a battery of 
obstacles, including (iv) suppressive immune infiltrate compris-
ing T regulatory cells (Tregs), myeloid-derived suppressor cells 
(MDSCs), tumor-associated macrophages, tumor-associated 
neutrophils (188), and immature DCs (189), (v) a range of 
suppressive molecules such as transforming growth factor beta 
(TGFβ) VEGF and adenosine, (vi) suppressive ligands including 
PD-L1/L2, VISTA, and FasL (190), (vii) competition for, and 
downregulation of, costimulatory ligands such as CD80/86, and 
(viii) T-cell-intrinsic regulatory mechanisms including PD-1 and 
CTLA-4 upregulation, and ultimately exhaustion (191) or anergy 
(192). Finally, (ix) the T-cells must function in an environment 
that is acidic, hypoxic (193), nutritionally depleted (194) and 
comprising toxic metabolic by-products such as lactic acid, 
glutamate, and ketone bodies (195) (summarized in Figure 4).
CAR T-Cell Coengineering and 
Combinatorial Therapy for Tumor Homing 
and Migration into the Tumor Bed
The predominant chemokine receptor mediating effector T-cell 
recruitment to tumors is CXCR3 via chemokines CXCL9 and 
CXCL10 (196). Chemokines commonly secreted in TMEs, 
however, rather than attracting cytotoxic T-cells often recruit 
inhibitory immune cells such as Tregs and MDSCs, whose 
presence is associated with poor patient prognosis (197). The 
chemokine CCL22, for example, present in breast and prostate 
cancer, mediates CCR4-dependent Treg trafficking (197, 198), 
while hypoxia-dependent expression of the chemokine ligand 
CCL28 in ovarian cancer recruits Tregs via CCR10 (199), and in 
pancreatic cancer the upregulation of CCL5 induces the migra-
tion of CCR5-expressing Tregs (200). Tregs are potent inhibitors 
of CD8+ T-cells as they compete for IL-2 (201), generate adeno-
sine by CD39/CD73 (202), and via CTLA-4 downregulate CD80/
CD86 on DCs that are needed by T-cells for costimulation (203) 
while upregulating indoleamine 2,3-dioxygenase-1 (IDO-1) in 
DCs (204, 205). MDSCs can be recruited to different TMEs by 
CCL2, CXCL5, CXCL12, and stem cell factor (206). They also 
inhibit tumor immunity by various mechanisms including the 
expression of arginase, TGFβ, cyclooxygenase 2 that controls 
prostaglandin E2 (PGE2) production (207) (a powerful repressor 
of TCR signaling), and IL-10. In addition, MDSCs can sequester 
cysteine and induce Tregs (188). One approach to direct CAR 
T-cells (Figure 5A) toward a tumor that does not express CXCL9 
or CXCL10 is to coengineer them with a borrowed chemokine 
receptor (Figure  5B). For example, CXCR2-engineered T-cells 
(208, 209) demonstrated improved localization and control of 
melanoma tumors expressing CXCL1 and CXCL8, chemokines 
that enable the migration of CXCR2+ monocytes.
In order to tackle the stroma, FAP-directed CAR T-cells have 
been developed, and in murine tumor models have been shown 
to slow tumor growth (49). The observation that in vitro cultured 
T-cells downregulate heparanase, an enzyme that is required for 
the degradation of heparin sulfate proteoglycans, the primary 
component of the extracellular matrix of tumor stroma, led to 
the development of CAR T-cells coengineered to secrete it (210) 
(Figure  5C). Such CAR T-cells may be potent against stroma-
rich solid tumors. Various approaches can be taken to normalize 
the tumor vasculature (42). For example, blocking endothelin 
B receptor (211), and the pharmacologic inhibition of VEGF 
and PGE2 to attenuate FasL expression, enables enhanced CD8+ 
T-cell influx and tumor control (187). In addition, CAR T-cells 
that disrupt the tumor vasculature and mediate tumor regression 
have been developed (212).
CAR T-Cell Coengineering and 
Combinatorial Therapy for Overcoming 
immunometabolic Challenges in the 
Tumor Bed
The solid TME is hostile for effector T-cells. As a result of high 
aerobic glycolysis by tumor cells, as well as the fact that nutrients 
and oxygen must be supplied, and waste removed, by an aber-
rant vasculature, tumors are typically nutrient depleted, hypoxic, 
acidic, and toxic. As previously described, low glucose levels and 
a lack of critical amino acids such as leucine and arginine will 
alter T-cell metabolism and directly impair their function (156, 
213, 214). Gene-engineering approaches to render CAR T-cells 
more competitive in nutrient acquisition, such as by overexpress-
ing transporters (Figure 5G), or to rewire their metabolism, may 
improve their activity in solid tumors. For example, overexpres-
sion of PPAR-gamma coactivator 1-α (PGC1-α), a transcriptional 
coactivator involved in mitochondrial biogenesis, could in part 
reverse metabolic exhaustion (decreased mitochondrial mass 
and function induced by chronic Akt signaling) of T-cells in the 
TME (215) (Figure  5I). Interestingly, modulating cholesterol 
metabolism can enhance antitumor response of CD8+ T-cells; 
both pharmacological inhibition and gene knockdown of the 
cholesterol esterification enzyme ACAT1 increased plasma 
membrane concentration of cholesterol, enabling more efficient 
immune synapse formation, TCR clustering, and enhanced sign-
aling (216). Whether such strategies would also augment CAR 
T-cell activity remains to be determined.
Various other immunometabolic gene-engineering strategies 
have been proposed for increasing the activity of TCR- or CAR-
engineered T-cells in the TME. With respect to the PD-1/PD-L1 
checkpoint blockade axis, at least three different approaches have 
been taken. PD-1 has been knocked down in T-cells (217, 218), 
hybrid receptors comprising the ectodomain of PD-1 and the 
endodomain of CD28 have been expressed to divert PD-L1 bind-
ing toward costimulatory intracellular signaling (219), and CAR 
FiGURe 4 | Barriers in the solid tumor microenvironment (TMe) that can hinder chimeric antigen receptor (CAR) T-cell activity. In order to mediate an 
antitumor response, CAR T-cells must first successfully home to and penetrate the tumor bed. Obstacles to these events include tumor chemokine and T-cell 
chemokine receptor mismatches, and various inhibitory mechanisms in the vasculature such as ICAM-1 downregulation. In the stroma, T-cells can be physically 
blocked by dense extracellular matrix and by inhibitory cancer-associated fibroblasts. The TME itself is also hostile, comprising a range of inhibitory immune cells, 
inhibitory receptors such as PD-L1 on tumor cells and immune infiltrate alike, and soluble molecules such as TGFβ that impair T-cell activity (some examples are 
shown). In addition, the TME is typically acidic, hypoxic, full of toxic metabolites, and nutrient depleted which can inhibit not only T-cell activity but also other immune 
infiltrate such as DCs that lose their ability to mature and provide support to T-cells. Moreover, some of these conditions promote protumoral immune cells.
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T-cells have been engineered to secrete anti-PD-L1 Abs (220), 
all of which have been reported to increase antitumor responses 
(Figures 5D,H,J). Others have knocked-down master regulators 
of T-cell activity such as the E3 ubiquitin ligase Cbl-b (Figure 5J) 
and have shown enhanced antitumor T-cell responses (221, 
222). microRNAs, such as miR155, have also been manipulated 
for enhanced tumor control (223, 224) (Figure 5K), and T-cells 
have been gene engineered to overexpress cytokines including 
IL-12 (225) and IL-15 (226) (Figure 5E) for improved activity. 
The advantage of secreted molecules is that they can support not 
only the T-cell that produces them but also endogenous immune 
cells in the TME. As a final example, coengineering CAR T-cells 
to constitutively express CD40L demonstrated enhanced T-cell 
proliferation and secretion of pro-inflammatory cytokines 
(Figure 5F). The CD40L+ CAR T-cells also increased the immu-
nogenicity of CD40+ tumor cells through the upregulation of 
costimulatory, adhesion, and human leukocyte antigen molecules, 
as well as the Fas death receptor, and they induced the maturation 
and secretion of IL-12 by monocyte-derived DCs (58).
The TME can also reprogram other immune infiltrate to the 
detriment of T-cell activity. For example, the maturation, func-
tion, and phenotype of DCs can be impaired by VEGF (227), IL-6, 
macrophage colony-stimulating factor (228), and TGFβ (229). In 
addition, PD-L1 expression by DCs can be induced by IL-10 and 
VEGF (230). It was also recently demonstrated that HIFα expres-
sion [the main transcriptional factors responding to limited 
oxygen supply (231)] elevates miR-210 in MDSCs, which in turn 
increases both arginase activity and the production of nitric oxide 
(232). Along with hypoxia (233), lactate, a major byproduct of 
aerobic glycolysis in tumor cells, can also directly and indirectly 
inhibit cytotoxic T  lymphocyte activity. Indeed, high lactate in 
the TME can block the export of endogenous lactate produced 
FiGURe 5 | T-cell coengineering strategies to target and attack solid tumors, and overcome immunometabolic barriers. Human T-cells, ideally minimally 
differentiated, can be gene-engineered ex vivo in various ways including transient RNA electroporation and stable genome integration by lentiviral transduction and 
sleeping beauty. (A) To enable tumor specificity, the T-cell can be engineered with a chimeric antigen receptor (CAR) directed against a surface-expressed tumor 
antigen (or a TCR against a target pMHC). (B) To enable tumor homing the T-cell can be coengineered to express a specific chemokine receptor that matches the 
chemokine profile of the tumor being targeted. (C) To better penetrate dense stroma CAR T-cells can be coengineered to secrete heparanase. (D) Instead of 
injecting the patient with checkpoint blockade monoclonal antibodies (mAbs), the T-cells can be gene engineered to secrete anti-PD ligand 1 (PD-L1) mAb. (e) The 
tumor microenvironment (TME) often lacks T-cell promoting cytokines, either because they are not produced, or because they are competitively consumed, such as 
IL-2 by T regulatory cells. Thus, CAR T-cells can be coengineered to forcibly secrete various cytokines that can serve not only to self-sustain the CAR T-cell but also 
to stimulate other adaptive and innate immune cells in the TME. (F) Forced expression of the stimulatory ligand CD40L will help activate antigen-presenting cells as 
well as upregulate adhesion molecules on endothelial cells. (G) The upregulation of nutrient transporters for glucose or amino acids may help to increase T-cell 
competition for limited resources in the TME. (H) Hybrid receptors such as ones comprising the extracellular domain of PD-1 fused to the endodomain of CD28 can 
turn a negative signal (i.e., from PD-L1) into one that costimulates the cell. This may be further improved by designing a higher affinity variant of PD-1. (i) The 
overexpression of intracellular proteins such as the transcription coactivator PGC1-α, can help to reverse metabolic exhaustion. (J) Using various techniques 
including CRISPR/cas9, it is possible to knockout gene expression such as of PD-1 and the master regulator Cbl-b to enhance T-cell activity in the TME. (K) 
microRNAs play an important role in T-cell activity and the overexpression of miR-155, for example, can be used to enhance sensitivity to homeostatic γc cytokines. 
Note that some of these approaches have yet to be demonstrated for engineered CAR T-cells.
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by aerobic glycolysis in T-cells via the gradient-dependent trans-
porter monocarboxylate transporter-1, and thereby disturb T-cell 
metabolism (234). Lactic acid can also promote M2-polarization 
and expression of arginase-1 by HIF-1α stabilization (235). 
Moreover, hypoxia, via HIF-1, can induce glycolysis as well as 
a switch from glucose to glutamine as the major substrate for 
FA synthesis in tumor cells (236), further depleting the TME of 
vital nutrients needed for T-cell function. Thus, pretreatment of 
tumors with inhibitors of either HIF-1 or metabolic enzymes 
could potentially impair the metabolic flexibility of cancer cells 
and inhibitory immune infiltrate, thus rendering tumors more 
sensitive to CAR T-cell transfer—the CAR T-cells will benefit 
from entering a more nutrient replete and less aggressive/sup-
pressive TME. Alternatively, metabolic drugs could be targeted 
to tumors with Abs, or the pharmacologic inhibitors could be 
designed in such a way that they are preferentially taken up by 
tumor cells.
A range of other strategies can be used to pretreat or 
cotreat tumors for enhanced responses to CAR T-cell therapy. 
Localized RT, for example, can reprogram the TME by various 
mechanisms including by inducing immunogenic cell death (52, 
237), supporting T-cell trafficking to the tumor (238), and by 
promoting the polarization of macrophages (239) from a sup-
pressive M2 (240) to M1 phenotype (241). An inhibitor of DNA 
methyltransferase 1 (catalyzes the methylation of genetic loci), 
5-aza-2′-deoxycytidine, has been used to enhance expression of 
the epigenetically silenced chemokines CXCL9 and CXCL10 in 
the TME and thereby promote T-cell infiltration and responses 
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to checkpoint blockade (242). CAR T-cells expressing CXCR3 
could benefit from such treatment. Cyclophosphamide, such as 
RT, can be used not only to direct tumor cell destruction but also 
to deplete Tregs from the TME and thereby enhance responses 
to immunotherapy (51). As a final example, IDO-1 inhibition is 
a powerful approach for promoting tumor immunity. IDO-1, the 
rate-limiting enzyme involved in the conversion of the essential 
amino acid tryptophan to its catabolic product kynurenine (Kyn) 
(204, 243), can be upregulated in DCs, by Tregs as mentioned 
above, as well as by tumor cells and myeloid cells in response to 
IFNγ (244, 245), and has been associated with poor prognosis for 
several types of cancer including ovarian (246), endometrial (247), 
colorectal (248), and lung (249). The depletion of tryptophan 
in the TME activates stress response kinases in T-cells, includ-
ing general control non-depressing 2 (GCN2), which detects 
uncharged tRNAs, and ultimately blocks T-cell proliferation and 
triggers the caspase pathway (250, 251). In addition, Kyn binds 
the arylhydrocarbon receptor, a ligand-activated transcription 
factor that promotes the polarization of naïve T-cells toward a 
Treg phenotype (251). Thus, IDO-1 inhibition promotes trypto-
phan availability for effector T-cells and limits Tregs in the TME.
CONCLUDiNG ReMARKS
Metabolism is an important driver of cancer progression that 
must be addressed in the context of CAR T-cell immunotherapy 
to improve clinical responses against solid tumors. High levels 
of aerobic glycolysis by tumor cells leads to an accumulation of 
metabolic by-products that, along with oxygen deprivation and 
low pH, can drive protumoral activity of various immune cells, 
including Tregs and M2 macrophages, as well as directly inhibit 
effector T-cell function. In addition, competition for critical 
nutrients, such as the amino acids tryptophan, glutamine, and 
arginine, as well as glucose, all contribute to the suppression of 
T-cell activity. Checkpoint pathways are intimately linked with 
the metabolic status of both tumor cells and T-cells; non-respon-
siveness to anti-PD-1 mAb has been linked to the upregulation 
of a metabolic gene-signature in tumors (35), whereas successful 
PD-L1 blockade has been demonstrated to block tumor cell 
glycolysis, thereby enhancing T-cell fitness (34).
Immunometabolic barriers can be targeted therapeutically 
prior to and/or during ACT to enhance responses to CAR T-cell 
therapy and to support endogenous immunity. In addition, 
CAR T-cells can be optimally designed based on the metabolic 
properties of the tumor being targeted and cultured to promote 
a less differentiated, long-lived phenotype that can efficiently 
self-renew and differentiate in  vivo into potent effector cells 
(252, 253). Further, CAR T-cells can be coengineered to enhance 
both their own activity and that of other immune cells in the 
TME. Emerging knowledge on the immunometabolic pathways 
regulating T-cell function in tumors offers new opportunities 
for gene-engineering to drive favorable T-cell energetics and 
optimize their activity. Next-generation CAR T-cell immuno-
therapy based on combinatorial engineering and treatments to 
reprogram T-cell properties and the TME offer unprecedented 
hope for curing solid tumors.
AUTHOR CONTRiBUTiONS
MI and GC conceived the manuscript; revised and approved the 
final manuscript. MI, RS, KS, and ND drafted the manuscript.
FUNDiNG
This project was supported by an ERC Advanced Grant to GC 
(1400206AdG-322875) and the Leenaards Foundation.
ReFeReNCeS
1. van der Merwe PA, Dushek O. Mechanisms for T cell receptor triggering. Nat 
Rev Immunol (2011) 11(1):47–55. doi:10.1038/nri2887 
2. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 
(1986) 39(6):585–9. doi:10.1136/jcp.39.6.585 
3. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani 
G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian 
cancer. N Engl J Med (2003) 348(3):203–13. doi:10.1056/NEJMoa020177 
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-
Pagès C, et  al. Type, density, and location of immune cells within human 
colorectal tumors predict clinical outcome. Science (2006) 313(5795):1960–4. 
doi:10.1126/science.1129139 
5. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture 
in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 
12(4):298–306. doi:10.1038/nrc3245 
6. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic 
significance of tumor-infiltrating T  cells in ovarian cancer: a meta-anal-
ysis. Gynecol Oncol (2012) 124(2):192–8. doi:10.1016/j.ygyno.2011. 
09.039 
7. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer 
immunoediting and its three component phases – elimination, equi-
librium and escape. Curr Opin Immunol (2014) 27:16–25. doi:10.1016/ 
j.coi.2014.01.004 
8. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. 
Improved survival with ipilimumab in patients with metastatic melanoma. N 
Engl J Med (2010) 363(8):711–23. doi:10.1056/NEJMoa1003466 
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, 
et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. 
N Engl J Med (2012) 366(26):2443–54. doi:10.1056/NEJMoa1200690 
10. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. 
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung 
cancer. N Engl J Med (2015) 373(2):123–35. doi:10.1056/NEJMoa1504627 
11. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A 
(anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. 
Nature (2014) 515(7528):558–62. doi:10.1038/nature13904 
12. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, 
et  al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s 
lymphoma. N Engl J Med (2015) 372(4):311–9. doi:10.1056/NEJMoa1411087 
13. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, 
et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl 
J Med (2015) 373(19):1803–13. doi:10.1056/NEJMoa1510665 
14. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama 
T, et  al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, 
in patients with platinum-resistant ovarian cancer. J Clin Oncol (2015) 
33(34):4015–22. doi:10.1200/JCO.2015.62.3397 
15. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 
blockade in tumors with mismatch-repair deficiency. N Engl J Med (2015) 
372(26):2509–20. doi:10.1056/NEJMoa1500596 
16. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. 
Combined nivolumab and ipilimumab or monotherapy in untreated mela-
noma. N Engl J Med (2015) 373(1):23–34. doi:10.1056/NEJMoa1504030 
17. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman 
WH, et  al. Survival, durable tumor remission, and long-term safety in 
13
Irving et al. Immunometabolic Barriers to T-Cell Therapy
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 267
patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 
32(10):1020–30. doi:10.1200/JCO.2013.53.0105 
18. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. 
PD-1 blockade induces responses by inhibiting adaptive immune resistance. 
Nature (2014) 515(7528):568–71. doi:10.1038/nature13954 
19. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. 
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl 
J Med (2014) 371(23):2189–99. doi:10.1056/NEJMoa1406498 
20. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. 
Cancer immunology. Mutational landscape determines sensitivity to PD-1 
blockade in non-small cell lung cancer. Science (2015) 348(6230):124–8. 
doi:10.1126/science.aaa1348 
21. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et  al. 
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant 
antigens. Nature (2014) 515(7528):577–81. doi:10.1038/nature13988 
22. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, 
et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in 
an ipilimumab-responsive melanoma. J Clin Oncol (2013) 31(32):e439–42. 
doi:10.1200/JCO.2012.47.7521 
23. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, 
et  al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carci-
noma. N Engl J Med (2016) 374(26):2542–52. doi:10.1056/NEJMoa1603702 
24. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-
L1 expression in the Merkel cell carcinoma microenvironment: association 
with inflammation, Merkel cell polyomavirus and overall survival. Cancer 
Immunol Res (2013) 1(1):54–63. doi:10.1158/2326-6066.CIR-13-0034 
25. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, et  al. 
Chemokine expression in melanoma metastases associated with CD8+ T-cell 
recruitment. Cancer Res (2009) 69(7):3077–85. doi:10.1158/0008-5472.
CAN-08-2281 
26. Salerno EP, Olson WC, McSkimming C, Shea S, Slingluff CL Jr. T cells in 
the human metastatic melanoma microenvironment express site-specific 
homing receptors and retention integrins. Int J Cancer (2014) 134(3):563–74. 
doi:10.1002/ijc.28391 
27. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the 
tumor microenvironment. Nat Immunol (2013) 14(10):1014–22. doi:10.1038/
ni.2703 
28. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et  al. 
Host type I IFN signals are required for antitumor CD8+ T cell responses 
through CD8{alpha}+ dendritic cells. J Exp Med (2011) 208(10):2005–16. 
doi:10.1084/jem.20101159 
29. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin sig-
nalling prevents anti-tumour immunity. Nature (2015) 523(7559):231–5. 
doi:10.1038/nature14404 
30. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. 
Commensal bacteria control cancer response to therapy by modulating the 
tumor microenvironment. Science (2013) 342(6161):967–70. doi:10.1126/
science.1240527 
31. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, 
et al. Commensal Bifidobacterium promotes antitumor immunity and facil-
itates anti-PD-L1 efficacy. Science (2015) 350(6264):1084–9. doi:10.1126/
science.aac4255 
32. Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. 
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbi-
ota. Science (2015) 350(6264):1079–84. doi:10.1126/science.aad1329 
33. Waickman AT, Powell JD. mTOR, metabolism, and the regulation of 
T-cell differentiation and function. Immunol Rev (2012) 249(1):43–58. 
doi:10.1111/j.1600-065X.2012.01152.x 
34. Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et  al. 
Metabolic competition in the tumor microenvironment is a driver of 
cancer progression. Cell (2015) 162(6):1229–41. doi:10.1016/j.cell.2015. 
08.016 
35. Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, Netto GJ, 
et al. The intratumoral balance between metabolic and immunologic gene 
expression is associated with anti-PD-1 response in patients with renal cell 
carcinoma. Cancer Immunol Res (2016) 4(9):726–33. doi:10.1158/2326-6066.
CIR-16-0072 
36. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan 
GQ, et  al. Durable complete responses in heavily pretreated patients with 
metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 
(2011) 17(13):4550–7. doi:10.1158/1078-0432.CCR-11-0116 
37. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for can-
cer: harnessing the T cell response. Nat Rev Immunol (2012) 12(4):269–81. 
doi:10.1038/nri3191 
38. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immu-
notherapy for human cancer. Science (2015) 348(6230):62–8. doi:10.1126/
science.aaa4967 
39. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive 
T-cell therapy for cancer. Immunol Rev (2014) 257(1):56–71. doi:10.1111/
imr.12132 
40. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer 
immunotherapy based on mutation-specific CD4+ T  cells in a patient 
with epithelial cancer. Science (2014) 344(6184):641–5. doi:10.1126/
science.1251102 
41. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity 
cycle. Immunity (2013) 39(1):1–10. doi:10.1016/j.immuni.2013.07.012 
42. Lanitis E, Irving M, Coukos G. Targeting the tumor vasculature to 
enhance T cell activity. Curr Opin Immunol (2015) 33:55–63. doi:10.1016/ 
j.coi.2015.01.011 
43. Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed 
and the non-T-cell-inflamed tumor microenvironment. Int Immunol (2016) 
28(8):383–91. doi:10.1093/intimm/dxw014 
44. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T  cells: 
CARs take the front seat for hematologic malignancies. Blood (2014) 
123(17):2625–35. doi:10.1182/blood-2013-11-492231 
45. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric 
antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 
(2014) 371(16):1507–17. doi:10.1056/NEJMoa1407222 
46. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strate-
gies that are mediated by tumor cells. Annu Rev Immunol (2007) 25:267–96. 
doi:10.1146/annurev.immunol.25.022106.141609 
47. Joyce JA, Fearon DT. T  cell exclusion, immune privilege, and the tumor 
microenvironment. Science (2015) 348(6230):74–80. doi:10.1126/science.
aaa6204 
48. Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to 
immunosuppressive mechanisms present within the tumor microenviron-
ment. Oncoimmunology (2014) 3(11):e970027. doi:10.4161/21624011.2014.
970027 
49. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et  al. 
Multifactorial T-cell hypofunction that is reversible can limit the efficacy of 
chimeric antigen receptor-transduced human T cells in solid tumors. Clin 
Cancer Res (2014) 20(16):4262–73. doi:10.1158/1078-0432.CCR-13-2627 
50. Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer 
with kinase inhibitors. J Clin Invest (2015) 125(5):1780–9. doi:10.1172/ 
JCI76094 
51. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in 
vaccine approaches: a current perspective. Cancer Res (2012) 72(14):3439–44. 
doi:10.1158/0008-5472.CAN-11-3912 
52. Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the 
game in immunotherapy. Trends Cancer (2016) 2(6):286–94. doi:10.1016/ 
j.trecan.2016.05.002 
53. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. 
Nat Rev Cancer (2012) 12(4):252–64. doi:10.1038/nrc3239 
54. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. 
Immunity (2013) 39(1):61–73. doi:10.1016/j.immuni.2013.07.005 
55. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immuno-
therapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 
14(8):561–84. doi:10.1038/nrd4591 
56. Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered 
T  cell immunotherapy for solid cancers. Nat Med (2016) 22(1):26–36. 
doi:10.1038/nm.4015 
57. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treat-
ment: immunomodulation, CARs and combination immunotherapy. Nat 
Rev Clin Oncol (2016) 13(5):273–90. doi:10.1038/nrclinonc.2016.25 
58. Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen 
DG, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells 
through constitutive CD40L expression. Mol Ther (2015) 23(4):769–78. 
doi:10.1038/mt.2015.4 
14
Irving et al. Immunometabolic Barriers to T-Cell Therapy
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 267
59. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol 
(2012) 13(10):907–15. doi:10.1038/ni.2386 
60. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor 
chimeric molecules as functional receptors with antibody-type specificity. 
Proc Natl Acad Sci U S A (1989) 86(24):10024–8. doi:10.1073/pnas.86.24.10024 
61. Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends 
Immunol (2015) 36(8):494–502. doi:10.1016/j.it.2015.06.004 
62. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, 
et  al. Tumor-specific T  cell activation by recombinant immunoreceptors: 
CD3 zeta signaling and CD28 costimulation are simultaneously required 
for efficient IL-2 secretion and can be integrated into one combined CD28/
CD3 zeta signaling receptor molecule. J Immunol (2001) 167(11):6123–31. 
doi:10.4049/jimmunol.167.11.6123 
63. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et  al. 
CD28 costimulation improves expansion and persistence of chimeric 
antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 
121(5):1822–6. doi:10.1172/JCI46110 
64. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary 
T cells with chimeric receptors: costimulation from CD28, inducible costim-
ulator, CD134, and CD137 in series with signals from the TCR zeta chain. 
J Immunol (2004) 172(1):104–13. doi:10.4049/jimmunol.172.1.104 
65. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, 
et al. Control of large, established tumor xenografts with genetically retar-
geted human T cells containing CD28 and CD137 domains. Proc Natl Acad 
Sci U S A (2009) 106(9):3360–5. doi:10.1073/pnas.0813101106 
66. Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to 
induce activation or cytokine production in peripheral T cells. Blood (2000) 
96(5):1999–2001. 
67. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis 
SA, et al. A phase I study on adoptive immunotherapy using gene-modified 
T  cells for ovarian cancer. Clin Cancer Res (2006) 12(20 Pt 1):6106–15. 
doi:10.1158/1078-0432.CCR-06-1183 
68. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et  al. 
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes 
genetically retargeted against carbonic anhydrase IX: first clinical experience. 
J Clin Oncol (2006) 24(13):e20–2. doi:10.1200/JCO.2006.05.9964 
69. Fesnak AD, June CH, Levine BL. Engineered T  cells: the promise and 
challenges of cancer immunotherapy. Nat Rev Cancer (2016) 16(9):566–81. 
doi:10.1038/nrc.2016.97 
70. Wang X, Riviere I. Clinical manufacturing of CAR T  cells: foundation of 
a promising therapy. Mol Ther Oncolytics (2016) 3:16015. doi:10.1038/
mto.2016.15 
71. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy 
using Sleeping Beauty to genetically modify clinical-grade T cells to target 
CD19. Immunol Rev (2014) 257(1):181–90. doi:10.1111/imr.12137 
72. Pluta K, Luce MJ, Bao L, Agha-Mohammadi S, Reiser J. Tight control of 
transgene expression by lentivirus vectors containing second-generation 
tetracycline-responsive promoters. J Gene Med (2005) 7(6):803–17. 
doi:10.1002/jgm.712 
73. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials 
and tribulations. Nat Rev Immunol (2009) 9(10):704–16. doi:10.1038/nri2635 
74. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P. 
A phage display selected fab fragment with MHC class I-restricted specificity 
for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene 
Ther (2001) 8(21):1601–8. doi:10.1038/sj.gt.3301570 
75. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting 
fibroblast activation protein in tumor stroma with chimeric antigen receptor 
T cells can inhibit tumor growth and augment host immunity without severe 
toxicity. Cancer Immunol Res (2014) 2(2):154–66. doi:10.1158/2326-6066.
CIR-13-0027 
76. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, 
et  al. 4-1BB costimulation ameliorates T  cell exhaustion induced by tonic 
signaling of chimeric antigen receptors. Nat Med (2015) 21(6):581–90. 
doi:10.1038/nm.3838 
77. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. 
Antitransgene rejection responses contribute to attenuated persistence of 
adoptively transferred CD20/CD19-specific chimeric antigen receptor redi-
rected T cells in humans. Biol Blood Marrow Transplant (2010) 16(9):1245–56. 
doi:10.1016/j.bbmt.2010.03.014 
78. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells 
expressing chimeric antigen receptors can cause anaphylaxis in humans. 
Cancer Immunol Res (2013) 1:26–31. doi:10.1158/2326-6066.CIR-13-0006 
79. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation 
by antibody-like immunoreceptors: increase in affinity of the single-chain 
fragment domain above threshold does not increase T cell activation against 
antigen-positive target cells but decreases selectivity. J Immunol (2004) 
173(12):7647–53. doi:10.4049/jimmunol.173.12.7647 
80. Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, et al. 
Interplay between T cell receptor binding kinetics and the level of cognate 
peptide presented by major histocompatibility complexes governs CD8+ 
T  cell responsiveness. J Biol Chem (2012) 287(27):23068–78. doi:10.1074/
jbc.M112.357673 
81. Schmid DA, Irving MB, Posevitz V, Hebeisen M, Posevitz-Fejfar A, Sarria JC, 
et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell 
function. J Immunol (2010) 184(9):4936–46. doi:10.4049/jimmunol.1000173 
82. Pameijer CR, Navanjo A, Meechoovet B, Wagner JR, Aguilar B, Wright CL, 
et  al. Conversion of a tumor-binding peptide identified by phage display 
to a functional chimeric T cell antigen receptor. Cancer Gene Ther (2007) 
14(1):91–7. doi:10.1038/sj.cgt.7700993 
83. Muniappan A, Banapour B, Lebkowski J, Talib S. Ligand-mediated cytolysis 
of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lym-
phocytes. Cancer Gene Ther (2000) 7(1):128–34. doi:10.1038/sj.cgt.7700100 
84. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. 
Specific recognition and killing of glioblastoma multiforme by interleukin 
13-zetakine redirected cytolytic T  cells. Cancer Res (2004) 64(24):9160–6. 
doi:10.1158/0008-5472.CAN-04-0454 
85. Zhang T, Barber A, Sentman CL. Generation of antitumor responses by 
genetic modification of primary human T  cells with a chimeric NKG2D 
receptor. Cancer Res (2006) 66(11):5927–33. doi:10.1158/0008-5472.
CAN-06-0130 
86. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, 
Mulligan RC. Antitumor activity of cytotoxic T lymphocytes engineered to 
target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A 
(2002) 99(10):7009–14. doi:10.1073/pnas.092562399 
87. Govers C, Sebestyén Z, Roszik J, van Brakel M, Berrevoets C, Szöőr Á, 
et  al. TCRs genetically linked to CD28 and CD3epsilon do not mispair 
with endogenous TCR chains and mediate enhanced T cell persistence and 
anti-melanoma activity. J Immunol (2014) 193(10):5315–26. doi:10.4049/
jimmunol.1302074 
88. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, 
et  al. A universal strategy for adoptive immunotherapy of cancer through 
use of a novel T-cell antigen receptor. Cancer Res (2012) 72(7):1844–52. 
doi:10.1158/0008-5472.CAN-11-3890 
89. Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, et al. Redirecting 
gene-modified T cells toward various cancer types using tagged antibodies. 
Clin Cancer Res (2012) 18(23):6436–45. doi:10.1158/1078-0432.CCR-12-1449 
90. Fousek K, Ahmed N. The evolution of T-cell therapies for solid malig-
nancies. Clin Cancer Res (2015) 21(15):3384–92. doi:10.1158/1078-0432.
CCR-14-2675 
91. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years 
in the making. Blood Rev (2016) 30(3):157–67. doi:10.1016/j.blre.2015. 
10.003 
92. Sharpe M, Mount N. Genetically modified T cells in cancer therapy: oppor-
tunities and challenges. Dis Model Mech (2015) 8(4):337–50. doi:10.1242/
dmm.018036 
93. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. 
Case report of a serious adverse event following the administration of T cells 
transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 
(2010) 18(4):843–51. doi:10.1038/mt.2010.24 
94. Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, et  al. 
Redirected activity of human antitumor chimeric immune receptors 
is governed by antigen and receptor expression levels and affinity 
of interaction. J Immunother (2007) 30(7):684–93. doi:10.1097/CJI. 
0b013e3180de5d90 
95. Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, et al. Affinity-tuned 
ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased ther-
apeutic index against tumors in mice. Cancer Res (2015) 75(17):3596–607. 
doi:10.1158/0008-5472.CAN-15-0159 
15
Irving et al. Immunometabolic Barriers to T-Cell Therapy
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 267
96. Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, et  al. 
Tuning sensitivity of CAR to EGFR density limits recognition of normal 
tissue while maintaining potent antitumor activity. Cancer Res (2015) 
75(17):3505–18. doi:10.1158/0008-5472.CAN-15-0139 
97. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, et al. 
Recognition of glioma stem cells by genetically modified T  cells targeting 
EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene 
Ther (2012) 23(10):1043–53. doi:10.1089/hum.2012.041 
98. Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively 
and safely target tumors. Curr Opin Immunol (2015) 33:9–15. doi:10.1016/ 
j.coi.2015.01.002 
99. Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, 
et al. Chimeric antigen receptor T Cells with dissociated signaling domains 
exhibit focused antitumor activity with reduced potential for toxicity in vivo. 
Cancer Immunol Res (2013) 1(1):43–53. doi:10.1158/2326-6066.CIR- 
13-0008 
100. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: 
a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol 
Ther Nucleic Acids (2013) 2:e105. doi:10.1038/mtna.2013.32 
101. Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, et al. 
Engineering customized cell sensing and response behaviors using synthetic 
notch receptors. Cell (2016) 164(4):780–91. doi:10.1016/j.cell.2016.01.012 
102. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et  al. 
Precision tumor recognition by T cells with combinatorial antigen-sensing 
circuits. Cell (2016) 164(4):770–9. doi:10.1016/j.cell.2016.01.011 
103. Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of 
therapeutic T cells through a small molecule-gated chimeric receptor. Science 
(2015) 350(6258):aab4077. doi:10.1126/science.aab4077 
104. Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety 
switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor 
T cells. Front Pharmacol (2014) 5:235. doi:10.3389/fphar.2014.00235 
105. Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell 
therapy products by suicide gene transfer. Front Pharmacol (2014) 5:254. 
doi:10.3389/fphar.2014.00254 
106. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: 
recognition and management. Blood (2016) 127(26):3321–30. doi:10.1182/
blood-2016-04-703751 
107. Cordoba SP, Choudhuri K, Zhang H, Bridge M, Basat AB, Dustin ML, et al. 
The large ectodomains of CD45 and CD148 regulate their segregation from 
and inhibition of ligated T-cell receptor. Blood (2013) 121(21):4295–302. 
doi:10.1182/blood-2012-07-442251 
108. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, et al. Antigen 
sensitivity of CD22-specific chimeric TCR is modulated by target epitope 
distance from the cell membrane. J Immunol (2008) 180(10):7028–38. 
doi:10.4049/jimmunol.180.10.7028 
109. Hombach AA, Schildgen V, Heuser C, Finnern R, Gilham DE, Abken H. 
T  cell activation by antibody-like immunoreceptors: the position of the 
binding epitope within the target molecule determines the efficiency of acti-
vation of redirected T cells. J Immunol (2007) 178(7):4650–7. doi:10.4049/
jimmunol.178.7.4650 
110. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader 
C, et al. The nonsignaling extracellular spacer domain of chimeric antigen 
receptors is decisive for in  vivo antitumor activity. Cancer Immunol Res 
(2015) 3(2):125–35. doi:10.1158/2326-6066.CIR-14-0127 
111. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genet-
ically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the 
extracellular moiety of chimeric antigen receptors avoids ‘ff-target’ activation 
and unintended initiation of an innate immune response. Gene Ther (2010) 
17(10):1206–13. doi:10.1038/gt.2010.91 
112. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham 
DE. The optimal antigen response of chimeric antigen receptors harboring 
the CD3zeta transmembrane domain is dependent upon incorporation of 
the receptor into the endogenous TCR/CD3 complex. J Immunol (2010) 
184(12):6938–49. doi:10.4049/jimmunol.0901766 
113. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation 
for universal T-cell based immunotherapy: T cells engineered to express a 
CD19-specific chimeric-antigen-receptor and eliminate expression of endog-
enous TCR. Blood (2012) 119(24):5697–705. doi:10.1182/blood-2012-01- 
405365 
114. Yang Y, Jacoby E, Fry TJ. Challenges and opportunities of allogeneic 
donor-derived CAR T  cells. Curr Opin Hematol (2015) 22(6):509–15. 
doi:10.1097/MOH.0000000000000181 
115. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O’Neill A, et al. The 
role of extracellular spacer regions in the optimal design of chimeric immune 
receptors: evaluation of four different scFvs and antigens. J Immunother 
(2005) 28(3):203–11. doi:10.1097/01.cji.0000161397.96582.59 
116. Liu L, Sommermeyer D, Cabanov A, Kosasih P, Hill T, Riddell SR. Inclusion 
of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat 
Biotechnol (2016) 34(4):430–4. doi:10.1038/nbt.3461 
117. Huang J, Zarnitsyna VI, Liu B, Edwards LJ, Jiang N, Evavold BD, et al. The 
kinetics of two-dimensional TCR and pMHC interactions determine T-cell 
responsiveness. Nature (2010) 464(7290):932–6. doi:10.1038/nature08944 
118. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory 
T cell subsets: function, generation, and maintenance. Annu Rev Immunol 
(2004) 22:745–63. doi:10.1146/annurev.immunol.22.012703.104702 
119. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. 
Acquisition of full effector function in vitro paradoxically impairs the in vivo 
antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 
115(6):1616–26. doi:10.1172/JCI24480 
120. Crompton JG, Sukumar M, Restifo NP. Uncoupling T-cell expansion from 
effector differentiation in cell-based immunotherapy. Immunol Rev (2014) 
257(1):264–76. doi:10.1111/imr.12135 
121. Gattinoni L, Restifo NP. Moving T memory stem cells to the clinic. Blood 
(2013) 121(4):567–8. doi:10.1182/blood-2012-11-468660 
122. Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, et  al. 
Identification, isolation and in  vitro expansion of human and nonhuman 
primate T stem cell memory cells. Nat Protoc (2013) 8(1):33–42. doi:10.1038/
nprot.2012.143 
123. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle 
CJ, et al. Chimeric antigen receptor-modified T cells derived from defined 
CD8+ and CD4+ subsets confer superior antitumor reactivity in  vivo. 
Leukemia (2016) 30(2):492–500. doi:10.1038/leu.2015.247 
124. Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which 
T-cell populations mediate highly effective adoptive immunotherapy? 
J Immunother (2012) 35(9):651–60. doi:10.1097/CJI.0b013e31827806e6 
125. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related 
T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells 
and are preserved by IL-7 and IL-15. Blood (2014) 123(24):3750–9. 
doi:10.1182/blood-2014-01-552174 
126. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific 
CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. 
Eur J Immunol (2014) 44(1):69–79. doi:10.1002/eji.201343718 
127. Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell 
SR. Generation of CD19-chimeric antigen receptor modified CD8+ 
T  cells derived from virus-specific central memory T  cells. Blood (2012) 
119(1):72–82. doi:10.1182/blood-2011-07-366419 
128. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy 
metabolism and the T-cell response. Nat Rev Immunol (2005) 5(11):844–52. 
doi:10.1038/nri1710 
129. Guppy M, Greiner E, Brand K. The role of the Crabtree effect and an 
endogenous fuel in the energy metabolism of resting and proliferating thy-
mocytes. Eur J Biochem (1993) 212(1):95–9. doi:10.1111/j.1432-1033.1993. 
tb17637.x 
130. van der Windt GJ, Pearce EL. Metabolic switching and fuel choice during 
T-cell differentiation and memory development. Immunol Rev (2012) 
249(1):27–42. doi:10.1111/j.1600-065X.2012.01150.x 
131. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et  al. The 
transcription factor Myc controls metabolic reprogramming upon 
T  lymphocyte activation. Immunity (2011) 35(6):871–82. doi:10.1016/j.
immuni.2011.09.021 
132. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, et al. 
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells 
to persistent antigen. Nat Immunol (2013) 14(11):1173–82. doi:10.1038/
ni.2714 
133. Wang T, Marquardt C, Foker J. Aerobic glycolysis during lymphocyte prolif-
eration. Nature (1976) 261(5562):702–5. doi:10.1038/261702a0 
134. Frauwirth KA, Thompson CB. Regulation of T  lymphocyte metabolism. 
J Immunol (2004) 172(8):4661–5. doi:10.4049/jimmunol.172.8.4661 
16
Irving et al. Immunometabolic Barriers to T-Cell Therapy
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 267
135. Rathmell JC, Vander Heiden MG, Harris MH, Frauwirth KA, Thompson 
CB. In the absence of extrinsic signals, nutrient utilization by lymphocytes 
is insufficient to maintain either cell size or viability. Mol Cell (2000) 
6(3):683–92. doi:10.1016/S1097-2765(00)00066-6 
136. Cretenet G, Clerc I, Matias M, Loisel S, Craveiro M, Oburoglu L, et  al. 
Cell surface Glut1 levels distinguish human CD4 and CD8 T  lymphocyte 
subsets with distinct effector functions. Sci Rep (2016) 6:24129. doi:10.1038/
srep24129 
137. Vuillefroy de Silly R, Ducimetière L, Yacoub Maroun C, Dietrich P-Y, 
Derouazi M, Walker PR. Phenotypic switch of CD8+ T  cells reactivated 
under hypoxia toward IL-10 secreting, poorly proliferative effector cells. Eur 
J Immunol (2016) 45:2263–75. doi:10.1002/eji.201445284 
138. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg 
effect: the metabolic requirements of cell proliferation. Science (2009) 
324(5930):1029–33. doi:10.1126/science.1160809 
139. Warburg O. On respiratory impairment in cancer cells. Science (1956) 
124(3215):269–70. 
140. Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O’Sullivan D, 
et al. Posttranscriptional control of T cell effector function by aerobic glycol-
ysis. Cell (2013) 153(6):1239–51. doi:10.1016/j.cell.2013.05.016 
141. Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. 
Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T  cell 
responses. Cell (2015) 162(6):1217–28. doi:10.1016/j.cell.2015.08.012 
142. Yaqoob P, Calder PC. Glutamine requirement of proliferating T  lym-
phocytes. Nutrition (1997) 13(7–8):646–51. doi:10.1016/S0899-9007(97) 
83008-0 
143. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic 
requirements of cell proliferation. Annu Rev Cell Dev Biol (2011) 27:441–64. 
doi:10.1146/annurev-cellbio-092910-154237 
144. Lochner M, Berod L, Sparwasser T. Fatty acid metabolism in the regulation 
of T  cell function. Trends Immunol (2015) 36(2):81–91. doi:10.1016/ 
j.it.2014.12.005 
145. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, 
et  al. Mitochondrial respiratory capacity is a critical regulator of CD8+ 
T  cell memory development. Immunity (2012) 36(1):68–78. doi:10.1016/ 
j.immuni.2011.12.007 
146. O’Sullivan D, van der Windt GJ, Huang SC, Curtis JD, Chang CH, Buck 
MD, et  al. Memory CD8(+) T  cells use cell-intrinsic lipolysis to support 
the metabolic programming necessary for development. Immunity (2014) 
41(1):75–88. doi:10.1016/j.immuni.2014.06.005 
147. van der Windt GJ, O’Sullivan D, Everts B, Huang SC, Buck MD, Curtis JD, 
et  al. CD8 memory T  cells have a bioenergetic advantage that underlies 
their rapid recall ability. Proc Natl Acad Sci U S A (2013) 110(35):14336–41. 
doi:10.1073/pnas.1221740110 
148. Buck MD, O’Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin 
DE, et  al. Mitochondrial dynamics controls T  cell fate through metabolic 
programming. Cell (2016) 166(1):63–76. doi:10.1016/j.cell.2016.05.035 
149. Gubser PM, Bantug GR, Razik L, Fischer M, Dimeloe S, Hoenger G, et al. 
Rapid effector function of memory CD8+ T  cells requires an immedi-
ate-early glycolytic switch. Nat Immunol (2013) 14(10):1064–72. doi:10.1038/ 
ni.2687 
150. Blagih J, Coulombe F, Vincent EE, Dupuy F, Galicia-Vázquez G, Yurchenko 
E, et  al. The energy sensor AMPK regulates T  cell metabolic adaptation 
and effector responses in vivo. Immunity (2015) 42(1):41–54. doi:10.1016/ 
j.immuni.2014.12.030 
151. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, 
et  al. mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 
460(7251):108–12. doi:10.1038/nature08155 
152. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et  al. 
Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 
(2009) 460(7251):103–7. doi:10.1038/nature08097 
153. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of 
T  lymphocytes. Annu Rev Immunol (2013) 31:259–83. doi:10.1146/
annurev-immunol-032712-095956 
154. Zheng Y, Delgoffe GM, Meyer CF, Chan W, Powell JD. Anergic T cells are 
metabolically anergic. J Immunol (2009) 183(10):6095–101. doi:10.4049/
jimmunol.0803510 
155. Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM, Cantrell DA. Control of 
amino-acid transport by antigen receptors coordinates the metabolic 
reprogramming essential for T  cell differentiation. Nat Immunol (2013) 
14(5):500–8. doi:10.1038/ni.2556 
156. Han JM, Jeong SJ, Park MC, Kim G, Kwon NH, Kim HK, et al. Leucyl-tRNA 
synthetase is an intracellular leucine sensor for the mTORC1-signaling 
pathway. Cell (2012) 149(2):410–24. doi:10.1016/j.cell.2012.02.044 
157. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, 
Kobayashi SV, et  al. CTLA-4 and PD-1 receptors inhibit T-cell activation 
by distinct mechanisms. Mol Cell Biol (2005) 25(21):9543–53. doi:10.1128/
MCB.25.21.9543-9553.2005 
158. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters 
T-cell metabolic reprogramming by inhibiting glycolysis and promoting 
lipolysis and fatty acid oxidation. Nat Commun (2015) 6:6692. doi:10.1038/
ncomms7692 
159. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human 
tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol 
Methods (1987) 102(1):127–41. doi:10.1016/S0022-1759(87)80018-2 
160. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. 
Interleukin-2 and inflammation induce distinct transcriptional programs 
that promote the differentiation of effector cytolytic T cells. Immunity (2010) 
32(1):79–90. doi:10.1016/j.immuni.2009.11.012 
161. Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer 
DC, et  al. IL-2 and IL-21 confer opposing differentiation programs to 
CD8+ T cells for adoptive immunotherapy. Blood (2008) 111(11):5326–33. 
doi:10.1182/blood-2007-09-113050 
162. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, 
Theoret MR, et al. IL-15 enhances the in vivo antitumor activity of tumor- 
reactive CD8+ T  cells. Proc Natl Acad Sci U S A (2004) 101(7):1969–74. 
doi:10.1073/pnas.0307298101 
163. Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, et al. Long-
lived antitumor CD8+ lymphocytes for adoptive therapy generated using 
an artificial antigen-presenting cell. Clin Cancer Res (2007) 13(6):1857–67. 
doi:10.1158/1078-0432.CCR-06-1905 
164. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray 
AP, et  al. Establishment of antitumor memory in humans using in  vitro- 
educated CD8+ T  cells. Sci Transl Med (2011) 3(80):80ra34. doi:10.1126/
scitranslmed.3002207 
165. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and 
affinity of the antigen-specific CD8 T  cell response. J Immunol (2005) 
175(4):2261–9. doi:10.4049/jimmunol.175.4.2261 
166. Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC. IL-7 promotes 
Glut1 trafficking and glucose uptake via STAT5-mediated activation of 
Akt to support T-cell survival. Blood (2008) 111(4):2101–11. doi:10.1182/
blood-2007-06-096297 
167. Cui G, Staron MM, Gray SM, Ho PC, Amezquita RA, Wu J, et  al. IL-7-
induced glycerol transport and TAG synthesis promotes memory CD8+ 
T  cell longevity. Cell (2015) 161(4):750–61. doi:10.1016/j.cell.2015. 
03.021 
168. Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, 
et  al. Mitochondrial membrane potential identifies cells with enhanced 
stemness for cellular therapy. Cell Metab (2016) 23(1):63–76. doi:10.1016/ 
j.cmet.2015.11.002 
169. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting 
glycolytic metabolism enhances CD8+ T cell memory and antitumor func-
tion. J Clin Invest (2013) 123(10):4479–88. doi:10.1172/JCI69589 
170. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, et al. Wnt signal-
ing arrests effector T cell differentiation and generates CD8+ memory stem 
cells. Nat Med (2009) 15(7):808–13. doi:10.1038/nm.1982 
171. van der Waart AB, van de Weem NM, Maas F, Kramer CS, Kester MG, 
Falkenburg JH, et al. Inhibition of Akt signaling promotes the generation of 
superior tumor-reactive T cells for adoptive immunotherapy. Blood (2014) 
124(23):3490–500. doi:10.1182/blood-2014-05-578583 
172. O’Sullivan D, Pearce EL. Targeting T  cell metabolism for therapy. Trends 
Immunol (2015) 36(2):71–80. doi:10.1016/j.it.2014.12.004 
173. Sikalidis AK. Amino acids and immune response: a role for cysteine, gluta-
mine, phenylalanine, tryptophan and arginine in T-cell function and cancer? 
Pathol Oncol Res (2015) 21(1):9–17. doi:10.1007/s12253-014-9860-0 
174. Rodriguez PC, Quiceno DG, Ochoa AC. l-Arginine availability regulates 
T-lymphocyte cell-cycle progression. Blood (2007) 109(4):1568–73. 
doi:10.1182/blood-2006-06-031856 
17
Irving et al. Immunometabolic Barriers to T-Cell Therapy
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 267
175. Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-arginine 
modulates T cell metabolism and enhances survival and anti-tumor activity. 
Cell (2016) 167(3):829–42.e13. doi:10.1016/j.cell.2016.09.031 
176. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et  al. 
CD19-targeted T  cells rapidly induce molecular remissions in adults with 
chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 
(2013) 5(177):177ra38. doi:10.1126/scitranslmed.3005930 
177. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, 
Feldman SA, et  al. T  cells expressing CD19 chimeric antigen receptors 
for acute lymphoblastic leukaemia in children and young adults: a phase 
1 dose-escalation trial. Lancet (2015) 385(9967):517–28. doi:10.1016/
S0140-6736(14)61403-3 
178. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et  al. 
Chimeric antigen receptor T cells persist and induce sustained remissions 
in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med (2015) 
7(303):303ra139. doi:10.1126/scitranslmed.aac5415 
179. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety 
and persistence of adoptively transferred autologous CD19-targeted T cells 
in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 
(2011) 118(18):4817–28. doi:10.1182/blood-2011-04-348540 
180. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. 
The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 
16(6):769–77. doi:10.1016/S1074-7613(02)00323-0 
181. Martinez-Forero I, Azpilikueta A, Bolaños-Mateo E, Nistal-Villan E, 
Palazon A, Teijeira A, et  al. T  cell costimulation with anti-CD137 mono-
clonal antibodies is mediated by K63-polyubiquitin-dependent signals from 
endosomes. J Immunol (2013) 190(12):6694–706. doi:10.4049/jimmunol. 
1203010 
182. Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD 
Jr, et al. Distinct signaling of coreceptors regulates specific metabolism path-
ways and impacts memory development in CAR T cells. Immunity (2016) 
44(2):380–90. doi:10.1016/j.immuni.2016.01.021 
183. Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, et  al. 
Dysfunctional oxidative phosphorylation makes malignant melanoma cells 
addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget 
(2013) 4(4):584–99. doi:10.18632/oncotarget.965 
184. Beatty GL, O’Hara M. Chimeric antigen receptor-modified T  cells for the 
treatment of solid tumors: defining the challenges and next steps. Pharmacol 
Ther (2016) 166:30–9. doi:10.1016/j.pharmthera.2016.06.010 
185. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. 
Human epidermal growth factor receptor 2 (HER2)-specific chimeric 
antigen receptor-modified T cells for the immunotherapy of HER2-positive 
sarcoma. J Clin Oncol (2015) 33(15):1688–96. doi:10.1200/JCO.2014.58.0225 
186. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor 
activity and long-term fate of chimeric antigen receptor-positive T cells in 
patients with neuroblastoma. Blood (2011) 118(23):6050–6. doi:10.1182/
blood-2011-05-354449 
187. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. 
Tumor endothelium FasL establishes a selective immune barrier promoting 
tolerance in tumors. Nat Med (2014) 20(6):607–15. doi:10.1038/nm.3541 
188. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor 
microenvironment: expect the unexpected. J Clin Invest (2015) 125(9):3356–
64. doi:10.1172/JCI80005 
189. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, et al. Cancer 
immunotherapy strategies based on overcoming barriers within the tumor 
microenvironment. Curr Opin Immunol (2013) 25(2):268–76. doi:10.1016/j.
coi.2013.02.009 
190. Chen L, Flies DB. Molecular mechanisms of T  cell co-stimulation and 
co-inhibition. Nat Rev Immunol (2013) 13(4):227–42. doi:10.1038/nri3405 
191. Wherry EJ. T cell exhaustion. Nat Immunol (2011) 12(6):492–9. doi:10.1038/
ni.2035 
192. Schwartz RH. T  cell anergy. Annu Rev Immunol (2003) 21:305–34. 
doi:10.1146/annurev.immunol.21.120601.141110 
193. Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh 
tumor microenvironment. Trends Cell Biol (2014) 24(8):472–8. doi:10.1016/ 
j.tcb.2014.06.001 
194. Zhang Y, Ertl HC. Starved and asphyxiated: how can CD8(+) T cells within a 
tumor microenvironment prevent tumor progression. Front Immunol (2016) 
7:32. doi:10.3389/fimmu.2016.00032 
195. Justus CR, Sanderlin EJ, Yang LV. Molecular connections between cancer 
cell metabolism and the tumor microenvironment. Int J Mol Sci (2015) 
16(5):11055–86. doi:10.3390/ijms160511055 
196. Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, et al. 
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell 
trafficking across tumour vascular checkpoints. Nat Commun (2015) 6:7458. 
doi:10.1038/ncomms8458 
197. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, 
Arfi V, et al. Regulatory T cells recruited through CCL22/CCR4 are selec-
tively activated in lymphoid infiltrates surrounding primary breast tumors 
and lead to an adverse clinical outcome. Cancer Res (2009) 69(5):2000–9. 
doi:10.1158/0008-5472.CAN-08-2360 
198. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, 
et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood 
of prostate cancer patients. J Immunol (2006) 177(10):7398–405. doi:10.4049/
jimmunol.177.10.7398 
199. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. 
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) 
cells. Nature (2011) 475(7355):226–30. doi:10.1038/nature10169 
200. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, 
et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits 
tumor growth in a murine model of pancreatic cancer. J Immunol (2009) 
182(3):1746–55. doi:10.4049/jimmunol.182.3.1746 
201. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ 
regulatory T cells induce cytokine deprivation-mediated apoptosis of effector 
CD4+ T cells. Nat Immunol (2007) 8(12):1353–62. doi:10.1038/ni1536 
202. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et  al. 
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory 
T  cells mediates immune suppression. J Exp Med (2007) 204(6):1257–65. 
doi:10.1084/jem.20062512 
203. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, 
et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 
322(5899):271–5. doi:10.1126/science.1160062 
204. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. 
Evidence for a tumoral immune resistance mechanism based on tryptophan 
degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 9(10):1269–74. 
doi:10.1038/nm934 
205. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced 
tolerance. J Clin Invest (2007) 117(5):1147–54. doi:10.1172/JCI31178 
206. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in 
the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 8(8):618–31. 
doi:10.1038/nrc2444 
207. Chen EP, Smyth EM. COX-2 and PGE2-dependent immunomodulation 
in breast cancer. Prostaglandins Other Lipid Mediat (2011) 96(1–4):14–20. 
doi:10.1016/j.prostaglandins.2011.08.005 
208. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, et al. Transduction 
of tumor-specific T cells with CXCR2 chemokine receptor improves migra-
tion to tumor and antitumor immune responses. Clin Cancer Res (2010) 
16(22):5458–68. doi:10.1158/1078-0432.CCR-10-0712 
209. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola 
FM, et  al. Redirecting migration of T  cells to chemokine secreted from 
tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 
13(16):1971–80. doi:10.1089/10430340260355374 
210. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase 
promotes tumor infiltration and antitumor activity of CAR-redirected T lym-
phocytes. Nat Med (2015) 21(5):524–9. doi:10.1038/nm.3833 
211. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. 
Endothelin B receptor mediates the endothelial barrier to T  cell homing 
to tumors and disables immune therapy. Nat Med (2008) 14(1):28–36. 
doi:10.1038/nm1699 
212. Santoro SP, Kim S, Motz GT, Alatzoglou D, Li C, Irving M, et al. T cells bear-
ing a chimeric antigen receptor against prostate-specific membrane antigen 
mediate vascular disruption and result in tumor regression. Cancer Immunol 
Res (2015) 3(1):68–84. doi:10.1158/2326-6066.CIR-14-0192 
213. Palmer CS, Ostrowski M, Balderson B, Christian N, Crowe SM. Glucose 
metabolism regulates T cell activation, differentiation, and functions. Front 
Immunol (2015) 6:1. doi:10.3389/fimmu.2015.00001 
214. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, 
et  al. Arginase I production in the tumor microenvironment by mature 
18
Irving et al. Immunometabolic Barriers to T-Cell Therapy
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 267
myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell 
responses. Cancer Res (2004) 64(16):5839–49. doi:10.1158/0008-5472.CAN- 
04-0465 
215. Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins 
SC, et al. The tumor microenvironment represses T cell mitochondrial bio-
genesis to drive intratumoral T cell metabolic insufficiency and dysfunction. 
Immunity (2016) 45(2):374–88. doi:10.1016/j.immuni.2016.08.009 
216. Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, et al. Potentiating the anti-
tumour response of CD8(+) T cells by modulating cholesterol metabolism. 
Nature (2016) 531(7596):651–5. doi:10.1038/nature17412 
217. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, 
et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist 
tumor-mediated inhibition. J Clin Invest (2016) 126(8):3130–44. doi:10.1172/
JCI83092 
218. Borkner L, Kaiser A, van de Kasteele W, Andreesen R, Mackensen A, Haanen 
JB, et al. RNA interference targeting programmed death receptor-1 improves 
immune functions of tumor-specific T cells. Cancer Immunol Immunother 
(2010) 59(8):1173–83. doi:10.1007/s00262-010-0842-0 
219. Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC. Tumor PD-L1 
co-stimulates primary human CD8(+) cytotoxic T cells modified to express 
a PD1:CD28 chimeric receptor. Mol Immunol (2012) 51(3–4):263–72. 
doi:10.1016/j.molimm.2012.03.023 
220. Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, et al. Chimeric 
antigen receptor T  cells secreting anti-PD-L1 antibodies more effectively 
regress renal cell carcinoma in a humanized mouse model. Oncotarget (2016) 
7(23):34341–55. doi:10.18632/oncotarget.9114 
221. Stromnes IM, Blattman JN, Tan X, Jeevanjee S, Gu H, Greenberg PD. 
Abrogating Cbl-b in effector CD8(+) T  cells improves the efficacy of 
adoptive therapy of leukemia in mice. J Clin Invest (2010) 120(10):3722–34. 
doi:10.1172/JCI41991 
222. Paolino M, Thien CB, Gruber T, Hinterleitner R, Baier G, Langdon WY, 
et al. Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell 
functions. J Immunol (2011) 186(4):2138–47. doi:10.4049/jimmunol. 
1003390 
223. Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, et al. 
The microRNA miR-155 controls CD8(+) T  cell responses by regulating 
interferon signaling. Nat Immunol (2013) 14(6):593–602. doi:10.1038/
ni.2576 
224. Ji Y, Wrzesinski C, Yu Z, Hu J, Gautam S, Hawk NV, et al. miR-155 augments 
CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing respon-
siveness to homeostatic gammac cytokines. Proc Natl Acad Sci U S A (2015) 
112(2):476–81. doi:10.1073/pnas.1422916112 
225. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, 
et  al. Tumor-targeted T  cells modified to secrete IL-12 eradicate systemic 
tumors without need for prior conditioning. Blood (2012) 119(18):4133–41. 
doi:10.1182/blood-2011-12-400044 
226. Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA. Primary 
human T lymphocytes engineered with a codon-optimized IL-15 gene resist 
cytokine withdrawal-induced apoptosis and persist long-term in the absence 
of exogenous cytokine. J Immunol (2005) 175(11):7226–34. doi:10.4049/
jimmunol.175.11.7226 
227. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf 
S, et al. Production of vascular endothelial growth factor by human tumors 
inhibits the functional maturation of dendritic cells. Nat Med (1996) 
2(10):1096–103. doi:10.1038/nm1096-1096 
228. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, et al. 
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors 
by tumor cells: role of interleukin-6 and macrophage colony-stimulating 
factor. Blood (1998) 92(12):4778–91. 
229. Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, et al. TGF-
beta 1 prevents the noncognate maturation of human dendritic Langerhans 
cells. J Immunol (1999) 162(8):4567–75. 
230. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of 
B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat 
Med (2003) 9(5):562–7. doi:10.1038/nm863 
231. Palazón A, Aragonés J, Morales-Kastresana A, de Landázuri MO, Melero I. 
Molecular pathways: hypoxia response in immune cells fighting or promot-
ing cancer. Clin Cancer Res (2012) 18(5):1207–13. doi:10.1158/1078-0432.
CCR-11-1591 
232. Noman MZ, Janji B, Hu S, Wu JC, Martelli F, Bronte V, et  al. Tumor-
promoting effects of myeloid-derived suppressor cells are potentiated by 
hypoxia-induced expression of miR-210. Cancer Res (2015) 75(18):3771–87. 
doi:10.1158/0008-5472.CAN-15-0405 
233. Vuillefroy de Silly R, Dietrich PY, Walker PR. Hypoxia and antitumor CD8+ 
T cells: an incompatible alliance? Oncoimmunology (2016) 5(12):e1232236. 
doi:10.1080/2162402X.2016.1232236 
234. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. 
Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 
(2007) 109(9):3812–9. doi:10.1182/blood-2006-07-035972 
235. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, 
et  al. Functional polarization of tumour-associated macrophages by 
tumour- derived lactic acid. Nature (2014) 513(7519):559–63. doi:10.1038/
nature13490 
236. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia 
and oncogenic mutations. J Clin Invest (2013) 123(9):3664–71. doi:10.1172/
JCI67230 
237. Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities 
leveraging immunity for the next oncology practice. CA Cancer J Clin (2016) 
67(1):65–85. doi:10.3322/caac.21358 
238. Burnette B, Fu YX, Weichselbaum RR. The confluence of radiotherapy and 
immunotherapy. Front Oncol (2012) 2:143. doi:10.3389/fonc.2012.00143 
239. Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotyp-
ical vs. functional differentiation. Front Immunol (2014) 5:514. doi:10.3389/
fimmu.2014.00514 
240. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by 
tumor-derived macrophages suppresses the expression of CD3 zeta chain of 
T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad 
Sci U S A (1996) 93(23):13119–24. doi:10.1073/pnas.93.23.13119 
241. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et  al. Low-
dose irradiation programs macrophage differentiation to an iNOS(+)/M1 
phenotype that orchestrates effective T  cell immunotherapy. Cancer Cell 
(2013) 24(5):589–602. doi:10.1016/j.ccr.2013.09.014 
242. Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic 
silencing of TH1-type chemokines shapes tumour immunity and immuno-
therapy. Nature (2015) 527(7577):249–53. doi:10.1038/nature15520 
243. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing 
indoleamine 2,3-dioxygenase inhibit T  cell responses. J Immunol (2002) 
168(8):3771–6. doi:10.4049/jimmunol.168.8.3771 
244. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 
2,3-dioxygenase, and tryptophan catabolism. FASEB J (1991) 5(11):2516–22. 
245. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation 
of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment 
is driven by CD8(+) T  cells. Sci Transl Med (2013) 5(200):200ra116. 
doi:10.1126/scitranslmed.3006504 
246. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, et  al. 
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene 
expression profiles of serous ovarian cancer cells. Clin Cancer Res (2005) 
11(16):6030–9. doi:10.1158/1078-0432.CCR-04-2671 
247. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, et al. 
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial 
cancer. Br J Cancer (2006) 95(11):1555–61. doi:10.1038/sj.bjc.6603477 
248. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler 
C, et  al. Prognostic value of indoleamine 2,3-dioxygenase expression in 
colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res (2006) 
12(4):1144–51. doi:10.1158/1078-0432.CCR-05-1966 
249. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. 
IDO is a nodal pathogenic driver of lung cancer and metastasis development. 
Cancer Discov (2012) 2(8):722–35. doi:10.1158/2159-8290.CD-12-0014 
250. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et  al. 
GCN2 kinase in T cells mediates proliferative arrest and anergy induction 
in response to indoleamine 2,3-dioxygenase. Immunity (2005) 22(5):633–42. 
doi:10.1016/j.immuni.2005.03.013 
251. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control 
of immune responses. Trends Immunol (2013) 34(3):137–43. doi:10.1016/ 
j.it.2012.10.001 
252. Kerkar SP, Restifo NP. Cellular constituents of immune escape within 
the tumor microenvironment. Cancer Res (2012) 72(13):3125–30. 
doi:10.1158/0008-5472.CAN-11-4094 
19
Irving et al. Immunometabolic Barriers to T-Cell Therapy
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 267
253. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treat-
ment: immunomodulation, CARs and combination immunotherapy. Nat 
Rev Clin Oncol (2016) 13(6):394. doi:10.1038/nrclinonc.2016.65 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Irving, Vuillefroy de Silly, Scholten, Dilek and Coukos. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permit-
ted, provided the original author(s) or licensor are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with these 
terms.
